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Abstract 
Daptomycin (DAP) is a cyclic anionic lipopeptide antibiotic that kills gram-positive 
bacteria via cell membrane distortion. It is currently approved for treatment of 
complicated infections caused by gram-positive bacteria, including methicillin-
resistant Staphylococcus aureus, vancomycin-resistant S. aureus, coagulase-negative 
staphylococci, penicillin-resistant streptococci and vancomycin-resistant enterococci. 
Recent studies showed that the bactericidal activity of DAP on the target membrane is 
dependent on Ca
2+
. DAP is also associated with membrane depolarization in the 
presence of phosphatidylglycerol (PG). Therefore, in this study, we aimed to 
investigate the binding behavior of DAP on the membrane of S. aureus cells as well 
as the specific interaction of DAP with target molecules.  
We first used highly inclined and laminated optical sheet (HILO) microscopy to 
visualize DAP location on the membrane of S. aureus cells. Then, we quantitatively 
analyzed DAP distribution on S. aureus cell membranes and its correlation with cell 
size and aggregate formation in a time- and concentration-dependent manner. We 
observed septum binding for the concentrations lower than the minimum inhibitory 
concentration (MIC) of DAP and for the concentration around the MIC until 10 min 
of incubation. However, overall membrane binding of DAP occurred at longer 
incubation times and higher DAP concentrations. This result was further supported by 
the super-resolution imaging of the localization of single DAP molecules on the 
membrane of S. aureus. We found that DAP accumulation correlated negatively with 
cell size but positively with aggregate formation.  
Thus, we further examined the colocalization of 5(6)-TAMRA-X, SE-labeled DAP 
(DAP-TMR) with the FtsW-GFP fusion protein and lipid II. FtsW is a bacterial cell 
division protein, which is positioned at the septum. For the short incubation interval, 
DAP-TMR localized to the septum and was colocalized with FtsW-GFP. For 
incubation times, DAP bound to the complete cell membrane but the distribution of 
FtsW-GFP remained unaffected. Furthermore, in cells stained with a BODIPY FL 
conjugate of vancomycin (Van-BDP FL), considerably less binding of DAP-TMR 
occurred, indicating that Van-BDP FL prevented the binding of DAP and that lipid II 
might be the target molecule of DAP. 
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Finally, we used fluid supported lipid bilayers to study the binding behavior of DAP 
on membranes with different lipid compositions. Bilayers were prepared on coverslips 
by vesicle fusion. The neutral phosphatidylcholine phospholipids were used as the 
matrix to which PG or/and bactoprenol lipids (C55-PP, C55-P, lipid II) were added. PG 
as well as the three bactoprenol lipids enhanced the binding of DAP. Surprisingly, 
addition of PG in bactoprenol-containing membranes significantly strengthened DAP 
binding, indicating that the bactoprenol lipids affect the binding of DAP and that the 
combination of PG and bactoprenol lipids is critical for the bactericidal mechanism of 
DAP. This explains the preferential binding of DAP to the septum. Our findings 
describe a new model for the mechanism of action of DAP. 
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1. Introduction 
1.1 A brief history of antibiotics  
The field of antibiotics has been explored extensively in academia and presented 
many breakthroughs as well as difficulties in the global evolutionary and human 
history scales 
[ 1 ]
. The discovery and use of antibiotics were turning points that 
revolutionized medicine in many respects, thereby saving countless human lives and 
enabling spectacular successes in genetic engineering, molecular biology, and other 
sequencing-related fields. .  
The concept of a “magic bullet”, which could selectively target only the disease-
causing microbes but not its host, was first introduced by P. Ehrlich around 1900. 
Following this concept, the anti-syphilis drug salvarsan (arsphenamine) was 
discovered via a systematic screening program in 1909. Later, in the early 1930s, the 
first sulfonamide drug named prontosil (sulfamidochrysoidine) was discovered and 
used clinically to treat a wide range of bacteria 
[2]
. At the same time, penicillin was 
discovered by A. Fleming in 1929, and its clinical use began in the early 1940s 
[3]
. In 
the meantime, “antibiotic” was first used as a noun by S. Waksman in 1941 to 
describe any small molecule produced by a microbe that antagonizes the growth of 
other microbes 
[4]
. Thus, the discovery of these first three antimicrobials, salvarsan, 
prontosil, and penicillin, marked the beginning of the antibiotic era, and was followed 
by the discovery of several new antibiotics in the 1950s. The period in the succeeding 
10-15 years was indeed the golden era of discovery and medicinal use of novel 
antibiotics 
[5]
. Human beings derived countless benefits from these antibiotics in the 
treatment and control of infectious, neoplastic, and viral diseases.   
1.2 Bacterial membrane components 
Bacterial cell membranes, which not only surround and protect the cytoplasm but also 
play a key role in bacterial cell structure, have been well studied since the 1950s 
[6]
. 
Bacterial membranes are structurally similar to eukaryotic cell membranes, except 
that bacterial membranes consist of saturated or monounsaturated fatty acids and 
usually do not contain sterols. Bacterial membrane composition varies with the 
18 
 
bacterial species, and also changes in response to environmental factors, such as 
temperature, pH, salinity, and osmolarity 
[7,8]
.  
The major lipid components identified and studied are diacyl-based 
glycerophospholipids containing two fatty acids and variable heads, such as 
phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylcholine (PC), 
cardiolipin (CL), lysyl-phosphatidylglycerol (LPG) and phosphatidylserine (PS) 
[9]
. In 
some bacteria, phosphatidyl-(N)-methylethanolamine (PME) and phosphatidyl-(N, 
N)-dimethylethanolamine (PDME) act as intermediates during PC synthesis
 [10,11]
. PG 
has been demonstrated as the second most plentiful lipid and has an essential function 
in bacterial membranes 
[9]
. The head group of PG can be modified by transfer of 
amino acids to form LPG, alanyl-PG (APG) or arginyl-PG (ArPG) 
[12,13]
. Most of the 
modified PGs have been reported in gram-positive bacteria, including Staphylococcus 
aureus, Listeria monocytogenes, Lactococcus plantarum and Bacillus subtilis 
[14,15,16]
, 
and a few modified PGs have been reported in some gram-negative bacteria such as 
Rhizobium tropici and Pseudomonas aeruginosa 
[ 17 , 18 , 19 ]
. PS is rarely found in 
bacterial membranes, as it is an intermediate in PE biosynthesis 
[20,21]
. Generally, PE, 
PG and CL comprise a large portion of the bacterial membrane phospholipids. 
Escherichia coli, the standard model used for studying bacterial membrane lipids, 
contains these three major phospholipids in its cell membrane: 70-80% PE, 20-25% 
PG, and 5% CL 
[22]
. 
In addition to these main membrane lipids, other varieties of lipids are synthesized by 
different types of bacteria. For instance, some bacteria contain membrane lipids that 
lack the phosphate group but contain the diacylglycerol (DAG) backbone, such as 
diacylglyceryl-N,N,N-trimethyl-homoserine (DGTS) 
[23,24]
, and glycophospholipids 
(GPLs) 
[ 25 ]
. Some bacteria contain bacterial membrane lipids without a DAG 
backbone, such as ornithine lipids (OLs), sulfonolipids, or sphingolipids (SLs) 
[26,27,28]
. 
Although the synthesis pathways or locations of these membranes are different, they 
serve different but equally important functions. 
Bacteria are classified into two major categories based on the structural differences in 
their cell walls via a special technique called Gram staining, devised by the Danish 
bacteriologist H. C. J. Gram in 1884 
[29]
. In this technique, the staining characteristics 
of bacteria are denoted as positive or negative, depending on whether the bacteria 
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retain the stain when observed under a microscope. Here, bacteria are stained with the 
crystal (or gentian) violet dye, washed with a decolorizing solution, and 
counterstained with safranin or fuchsine. Bacteria that retain the crystal violet dye are 
called gram-positive bacteria, whereas the ones that do not retain crystal violet and 
are stained red or pink are classified as gram-negative bacteria 
[29]
. This property of 
stain retention is associated with the outer layer of bacterial cells. Gram-positive 
bacteria do not have an outer cell membrane but have a thick layer of peptidoglycan 
(PGN), which absorbs the Gram stain. In contrast, gram-negative bacteria possess an 
outer membrane and cannot retain the crystal violet stain after the decolorization step; 
alcohol used in this stage degrades their outer membrane making the cell wall more 
porous and incapable of retaining the crystal violet stain. Furthermore, their PGN 
layer is considerably thinner and is sandwiched between an inner cell membrane and 
the outer membrane, causing them to take up the counterstain (safranin or fuchsine) 
and appear red or pink. Despite their thicker PGN layer, gram-positive bacteria are 
more susceptible to antibiotics than gram-negative bacteria are, owing to the absence 
of the outer membrane. 
Gram-positive bacteria differ from gram-negative bacteria in several ways. First, 
unlike gram-positive bacteria, gram-negative bacteria contain an outer membrane 
[30]
, 
gram-positive bacteria only possess a single lipid membrane (also called plasma 
membrane) surrounded by a cell wall composed of a thick layer of PGN and 
lipoteichoic acid (LTA) 
[ 31 ]
. In some gram-negative bacteria, the PGN layer is 
considerably thicker than that generally present in other gram-negative bacteria, thus 
enabling them to withstand the turgor pressure exerted on the plasma membrane. 
Bacterial cell membranes are composed of 40 % phospholipid and 60 % protein. As 
gram-positive bacteria lack the outer membrane to hold extracellular proteins, all 
these structural and enzymatic proteins are present in or near the cell membrane; some 
proteins are embedded or inserted into the membrane, located on the membrane, or 
covalently attached to the PGN 
[ 32 ]
. Thus, many different types of proteins are 
associated with the cell membrane. 
Gram-negative bacteria are surrounded by two membranes, the inner membrane (also 
called plasma membrane) and the outer membrane. The inner and outer membranes 
differ in their phospholipid composition and organization 
[33]
. The outer membrane, 
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present outside the rigid cell wall and composed of lipopolysaccharide (LPS), 
phospholipids, and proteins, is a distinguishing feature of gram-negative bacteria. It 
provides the bacterium with a hydrophilic surface, owing to the presence of LPS 
molecules. The LPS of a gram-negative bacterium is composed of three different 
parts: lipid-A, the core polysaccharide comprising the inner and the outer cores, and 
the O-specific polysaccharide chains projecting outward 
[ 34 ]
. Several proteins are 
located in the outer membrane and are involved in several important functions, such 
as adherence, nutrient acquisition, signaling, and protection of cells from the 
environment 
[35,36]
. Most of the outer membrane proteins can be divided into two 
classes, lipoproteins and β-barrel proteins [37]. Generally some porin proteins provide 
hydrophilic trans-membrane channels that enable the transport of small hydrophilic 
solutes through the outer membrane, whereas the outer membrane acts as a strong 
permeability barrier to macromolecules and hydrophobic compounds; therefore, 
gram-negative bacteria are relatively resistant to many antibiotics 
[38]
. In addition, as a 
phospholipid bilayer, the lipid portion of the outer membrane is impermeable to 
charged molecules. 
 
Figure 1: Differences in the cell membranes of gram-positive and gram-negative bacteria. Picture 
adopted from Silhavy et al. 2010 
[39]
. 
Fig. 1 shows the differences in the cell membranes of gram-positive and gram-
negative bacteria. Both have a cell wall composed of peptidoglycan (PGN): in gram-
positive bacteria, the wall is thick, whereas in gram-negative bacteria, the wall is thin. 
Moreover, an outer membrane containing lipopolysaccharides and lipoproteins 
surrounds the cell wall in gram-negative bacteria. Porins are cell membrane proteins 
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that allow transport of substances through the outer membrane of gram-negative 
bacteria. In gram-positive bacteria, LTA anchors the cell wall to the cell membrane. 
Bacterial plasma membranes are critical structures that play vital roles in multiple 
cellular processes 
[40,41,42]
. As hydrophobic films, they provide a physical barrier to 
separate the aqueous cytoplasm from the environment. They provide selective 
permeability to allow substrate uptake and product release. They also prevent the loss 
of essential interior compartments through leakage but allow the import and export of 
specific ions and molecules, to maintain a stable chemical environment required for 
the biological processes of the living cell. In addition, bacterial plasma membranes 
support several different crucial cell processes, including cell division, differentiation, 
protein secretion, and supplementary protein functions, and are the sites for synthesis 
of cell wall constituents. To understand their role in the formation of the cell wall 
constituents, it is essential to understand cell wall formation. As an example, the 
involvement of the plasma membrane in the synthesis of cell wall PGN in gram-
positive bacteria has been briefly described in Fig. 2. 
1.3 Bacterial cell wall biosynthesis 
PGN, the major constituent of the bacterial cell wall, is composed of long glycan 
chains cross-linked by peptide bridges 
[43]
. It forms a large elastic meshwork that 
covers the entire cell to provide the strength and rigidity to cell walls in both gram-
positive and gram-negative bacteria. Thus, PGN serves to protect the cell from 
damage, bear the stress from the osmolarity of the cytoplasm, and maintain the 
characteristic cell shape. PGN biosynthesis is a multistep process containing three 
different stages, each involving a series of enzyme-catalyzed reactions (Fig. 2) 
[44,45]
. 
Briefly, the first stage occurs in the cytoplasm and involves the synthesis of the 
soluble activated nucleotide precursor UDP-N-acetylmuramyl-pentapeptide (UDP-
MurNAc-pentapeptide) and UDP-N-acetylglucosamine (UDP-GlcNAc) 
[46]
. Here, the 
Mur ligases catalyze the synthesis of the peptide moiety 
[47]
. The pentapeptide in this 
synthesized sugar-peptide moiety is critical for the cross-linking of fully modified 
strands in the final step 
[48]
. In the second stage, two kinds of bactoprenol lipids, lipid 
I and lipid II, are synthesized on the cytoplasmic membrane. The phospho-MurNAc-
pentapeptide moiety of UDP-MurNAc-pentapeptide is linked to the membrane anchor 
undecaprenyl-phosphate (C55-P) by the translocase MraY, yielding lipid I (C55-PP-
22 
 
MurNAc-pentapeptide). Then, GlcNAc from UDP-GlcNAc is added to lipid I by the 
transferase MurG, resulting in the formation of lipid II (C55-PP-GlcNAc-MurNAc-
pentapeptide), which is the basic building block for direct formation of the cross-
linked PGN in bacteria 
[45]
. Once synthesized, lipid II is further modified and 
subsequently translocated across the cytoplasmic membrane with the help of a 
specific protein (translocase or flippase, such as FtsW) to the periplasm 
[ 49 , 50 ]
. 
Thereafter, in the third and final stage of PGN biosynthesis, lipid II is incorporated 
into the polymerized disaccharide moieties to form a PGN network at the exterior 
surface of the cell 
[51,52]
. This process is achieved mainly by the activity of penicillin-
binding proteins (PBPs) and transglycosylation and transpeptidation reactions to form 
the glycosidic and peptide bonds of the PGN, respectively 
[53,54]
. The lipid carrier, 
C55-PP, is released by the transglycosylase reaction and then flipped back across the 
bacterial membrane after dephosphorylation to enter a new synthesis cycle (Fig. 2).  
 
Figure 2: Schematic representation of peptidoglycan biosynthesis. Synthesis starts in the 
cytoplasm with the conversion of uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) to the 
final soluble precursor UDP-N-acetylmuramyl-pentapeptide (UDP-MurNAc-pentapeptide), 
catalyzed by the sequential action of enzymes. In the membrane-linked steps, lipid I and lipid II 
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are successively formed at the inner face of the membrane by MraY and MurG. Finally, lipid II is 
translocated across the membrane and incorporated in the growing peptidoglycan network through 
the activity of penicillin-binding proteins (PBPs). C55-PP and C55-P represent undecaprenyl 
pyrophosphate and undecaprenyl phosphate, respectively. 
C55-P, also called bactoprenol, is an important lipid in the cytoplasmic membrane. It 
plays a crucial role in PGN biosynthesis and is involved in the synthesis of other cell 
wall polymers 
[55,56,57]
. Several pathways of the C55-P metabolism via phosphatases 
and kinases have been demonstrated in bacteria (Fig. 3)  
[58,59,60]
.  
 
Figure 3: Metabolism of undecaprenyl phosphate (C55-P) in bacteria. Steps 1-4 are catalyzed by 
undecaprenyl pyrophosphate synthase (UppS), undecaprenyl pyrophosphate phosphatase (UppP), 
undecaprenyl phosphokinase, and undecaprenyl phosphate phosphatase, respectively. Figure from 
A. Bouhss et al., 2008 
[61]
. 
The precursor for C55-P, undecaprenyl pyrophosphate (C55-PP), is synthesized by 
undecaprenyl pyrophosphate synthase (UppS) 
[ 62 ]
. The recycling of C55-P 
(dephosphorylation of C55-PP to C55-P, further re-phosphorylation, and 
dephosphorylation again to C55-P) during PGN biosynthesis enables the cell to 
transport newly synthesized hydrophilic sugar-peptide moieties from the aqueous 
environment of the cytoplasm, across the hydrophobic membrane, to the exterior 
periplasm for further growth of the three-dimensional PGN network. 
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1.4 Daptomycin 
1.4.1 History, structure and biosynthesis  
Brief history and discovery  
Daptomycin (DAP), the naturally occurring fermentation product of Streptomyces 
roseosporus, is an antimicrobial lipopeptide with potent in vitro bactericidal activity 
against most gram-positive bacteria, including multiple antibiotic-resistant and -
susceptible strains 
[63,64,65]
. 
DAP was initially discovered by Eli Lilly & Company in the early 1980s, but the 
clinical trials were shelved in 1991 owing to the adverse effects and potential toxicity 
problems 
[66,67]
. Cubist Pharmaceuticals Inc. licensed the global rights for DAP from 
Eli Lilly & Company in 1997 and clinical trials recommenced in 1999 
[68]
. After 
intensive clinical trials, the United States Food and Drug Administration (FDA) and 
the European Medicines Agency (EMEA) approved DAP in September 2003 and 
January 2006, respectively for the treatment of complicated skin and skin structure 
infections (cSSSI) associated with methicillin-susceptible and methicillin-resistant S. 
aureus (MSSA and MRSA respectively), Streptococcus pyogenes, Streptococcus 
agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis 
(vancomycin-susceptible only) 
[69]
. Since 2007, it is distributed in Europe by Novartis. 
Since its introduction in clinical practice in 2003, DAP was approved as the key 
antibiotic for effective treatment of a variety of infections caused by gram-positive 
bacteria, such as skin and soft tissue infections, uncomplicated bacteremia, and right-
sided endocarditis 
[70]
. Moreover, the bactericidal activity of DAP was shown to be 
equal to or even higher than that of vancomycin, linezolid, and quinupristin-
dalfopristin 
[64]
. DAP efficaciously reduces bacterial growth in a concentration-
dependent manner 
[71,72]
. 
Structure  
DAP is an acidic cyclic lipopeptide antibiotic 
[73]
. Structurally, DAP consists of a 
highly lipophilic 10-amino acid fatty acid side chain linked to the N- terminal 
tryptophan of a 13-member peptide which is cyclized by an intramolecular ester bond 
to form a core 10-membered ring with a 3-residue side chain 
[67] 
(Fig. 4). DAP has 
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different stereochemically distinct amino acid residues: D-aspartate at position 2, D-
alanine (D-Ala) at position 8, and D-serine at position 11. The amino acid residues 
with L-stereochemistry are the normal isomeric forms of amino acids found in 
proteins. Furthermore, DAP contains three uncommon amino acid residues, ornithine 
at position 6, 3-methylglutamate at position 12, and kynurenine at position 13. DAP 
contains two aromatic residues (Trp-1 and Kyn-13) that are intrinsically fluorescent 
[137]
. Kynurenine is responsible for forming the ester bond with threonine that 
completes the cyclic structure 
[74]
. Owing to this unique structure, DAP exhibits a 
novel mechanism of action 
[75]
. 
 
Figure 4: Chemical structure of daptomycin. Picture adopted from Cubicin, 2003 
[69]
. 
The chemical name of DAP is N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-
threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-
methyl-L-glutamyl-3-anthraniloyl-L-alanine ε1-lactone. DAP has a chemical formula 
of C72H101N17O26 and a molecular weight of 1620.67 g/mol 
[69]
. 
Biosynthesis  
DAP, the first approved lipopeptide antibiotic, is a natural secondary metabolite 
produced via n-decanoic acid-directed fermentation in Streptomyces roseosporus 
[76]
. 
During the fermentation, Streptomyces roseosporus produces a complex combination 
of lipopeptides called the A21978C complex, which includes several lipopeptide 
structures. Generally, the analogs of A21978C contain chains consisting of 13 D- and 
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L-amino acids, linked by an ester bond between the carboxyl group of L-kynurenine13 
(Kyn) and the hydroxyl group of L-Thr4 to form a 10-macrolactone ring with three 
exocyclic residues
 [77]
. Antimicrobial activity requires at least 4-8 carbons in the fatty 
acyl side chain, with longer chains showing higher antimicrobial activity. The 
lipopeptides of the A21978C complex have different long-chain fatty acid tails, and 
these fatty acyl moieties are connected to the N-terminal of the tryptophan residue at 
position 1 of the amino acid chain, and enable distinction between the different types 
of A21978C complex components 
[74,78]
.  
During the fermentation of Streptomyces roseosporus the three major components, 
A21978C1-3 with branched 11-, 12-, or 13-carbon chain fatty acids, are produced 
[79]
. 
The A21978C complex is unique to Streptomyces roseosporus, but other similar 
compounds can also be found in the A21978C complex, such as the calcium-
dependent antibiotic (CDA) in Streptomyces coelicolor 
[80,81] 
and members of the 
A54145 family in Streptomyces fradiae 
[73,82]
.  
DAP is the N-decanoyl analog of the A21978C lipopeptide factor C1 and commonly 
contains a straight lipid side-chain with only 10 carbon atoms to form the n-decanoyl 
tail of the molecule.  
Generally, ribosomes are considered the protein builders and protein synthesizers of a 
cell; they link one amino acid at a time and build long polypeptide chains 
[ 83 ]
. 
However, some important antibiotic lipopeptides such as DAP, vancomycin, 
cyclosporin, and β-lactams are not produced by ribosomes but are biosynthesized by 
the large enzyme complexes called non-ribosomal peptide synthetases (NRPSs) 
[84]
. 
Typically, NRPS is composed of three catalytic domains, adenylation (A), 
condensation (C), and thiolation (T) domains; these domains work collectively to 
recognize specific amino acids and constitute them in the correct sequence during one 
cycle of this non-ribosomal peptide biosynthesis 
[ 85 ]
. Often, a fourth subunit is 
responsible for the catalytic release of the mature non-ribosomal peptide from the 
enzyme complex.   
In Streptomyces roseosporus, DAP is synthesized by a large NRPS via a thiotemplate 
mechanism 
[86,87]
. A 128 kb region of Streptomyces roseosporus DNA was verified to 
contain the DAP biosynthetic gene cluster (dpt) containing the tandemly arranged 
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genes dptA, dptBC, and dptD, which encode the three catalytic subunits of NRPS (Fig. 
5). Each subunit contains two to six modules and is responsible for one step of 
particular amino acid incorporation into the non-ribosomal peptide 
[88]
. 
 
Figure 5: Biosynthesis of the daptomycin precursor. Picture adopted from Nakhate et al., 2013 
[89]
. 
Other neighboring genes are also likely to be involved in the constitution of DAP. The 
genes dptE and dptF located upstream of the NRPS genes show sequence similarities 
to the genes encoding acyl-CoA ligase and acyl carrier protein, respectively. Their 
products are probably involved in the acylation of the first amino acid, N-terminal 
tryptophan (Trp), required to initiate DAP biosynthesis. Other contiguous downstream 
genes, including dptG, dptH, dptI, and dptJ, also have important functions in the 
biosynthesis of daptomycin. dptG is predicted to regulate the expression or export of 
antibiotics, and dptH may be involved in enhancing the efficiency of DAP production 
by clearing misincorporated substrates that block the pathway. dptI probably 
functions in conjunction with formation of the non-proteinogenic amino acids L-3-
methylglutamic acid in vivo. The dptJ gene may encode the tryptophan 2,3-
dioxygenase, which is involved in the conversion of Trp to Kyn  
[90,91]
. 
The scientists at Eli Lilly developed a DAP production process by feeding decanoic 
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acid during fermentation 
[92]
. Feeding other fatty acid structures during fermentation 
experiments resulted in production of different lipophilic tails of the core structure 
[93]
. 
However, DAP is formed as the main product when decanoic acid fed during 
fermentation 
[74,78]
. After chemical and enzymatic modification, DAP showed rapid in 
vitro antimicrobial activity against selected gram-positive bacteria 
[67]
.  
The understanding of the NRPS structure, DAP synthesis strategy, and the cloned dpt 
gene cluster not only provides an opportunity to study the biosynthesis of DAP and 
other lipopeptides, but also offers a chance to explore new and better methods to build 
novel lipopeptide antibiotics by pathway engineering 
[94,95]
.  
1.4.2 Putative mode of action  
1.4.2.1 Action mechanism of general antibiotics 
Development of antibiotics for the treatment of bacterial infections has revolutionized 
medical care and has remarkably reduced human morbidity and mortality. To be 
effective against bacteria, antibiotics should basically fulfill the following three 
conditions: the antibiotic must be specific to one or more susceptible targets in the 
cell; the dose of the antibiotic must be sufficient; and the antibiotic must not be 
inactivated or modified 
[96,97]
. Moreover, the antibacterial drug should show selective 
toxicity towards bacteria but not its host organism; namely, it should act on a unique 
target present in bacterial special structures or involved in their metabolic processes. 
On the basis of this criterion of selective toxicity, many antibacterial drugs function 
by targeting components of the bacterial cell. Antibiotic actions occur via the 
following five major mechanisms: i) interference with cell wall synthesis, ii) 
inhibition of protein synthesis, iii) interference with nucleic acid synthesis, iv) 
breakdown of the cell membrane structure or function, and v) inhibition of a 
metabolic pathway 
[98]
. Fig. 6 illustrates examples of the most common targets of 
antibiotics, antibiotic drugs, and their mode of actions. 
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Figure 6: General antibiotic action mechanisms and target sites of several antibiotic 
representatives. Sketch adopted from Chakraborty et al., 2012 
[99]
. 
As we have briefly described the biosynthesis of the cell wall (PGN) and the function 
of cell membrane components in PGN formation in the earlier sections, we describe 
the mechanism underlying antibiotic-induced inhibition of cell wall biosynthesis as an 
example. As mentioned earlier, bacterial cell wall is mainly composed of PGN, which 
is synthesized via a complex pathway that occurs in the cytoplasm and the periplasm 
[43]
. As PGN synthesis proceeds via several steps involving multiple enzyme-
catalyzed reactions, the enzymes in each step can be targeted and inhibited by several 
classes of antibiotics (Fig. 7), thereby resulting in rapid cell lysis and death 
[100,101]
. 
The main reactions and the enzymes involved in PGN synthesis, and the 
corresponding inhibitors are as follows: 
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Figure 7: Inhibition sites for main antibiotics in the peptidoglycan biosynthesis pathway. Picture 
taken from Schneider and Sahl, 2011 
[101]
.  
i) Formation of UDP- MurNAc from GlcNAc. PGN synthesis begins in the cytoplasm 
with the formation of UDP-MurNAc from UDP-GlcNAc and phosphoenolpyruvate 
(PEP) by the enzyme UDP-GlcNAc enolpyruvate transferase (MurA) 
[102]
. MurA is 
the target of fosfomycin, which is a broad-spectrum antibiotic and is structurally 
similar to both glycerophosphate and PEP. When the catalytic site of MurA is 
exposed during formation of a binary complex with UDP-GlcNAc, fosfomycin binds 
to MurA covalently, causing irreversible MurA inactivation 
[103,104]
. 
ii) Attachment of a pentapeptide to MurNAc. A pentapeptide containing the five 
amino acids, L-Ala, D-isoGlu, L-Lys, and the D-Ala–D-Ala dipeptide, is added to 
UDP-MurNAc in four sequential steps to form UDP-MurNAc-pentapeptide 
[105,106]
. 
Here, two enzymes, D-Ala racemase and D-Ala ligase, which convert L-Ala to D-Ala 
and create a peptide bond between two D-Ala residues respectively, are effectively 
targeted and inhibited by cycloserine 
[107,108]
. 
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iii) Attachment of UDP-MurNAc-pentapeptide to C55-P and formation of lipid I. The 
final cytoplasmic precursor UDP-MurNAc-pentapeptide is transferred to C55-P, a 
carrier lipid, by the membrane-bound phospho-MurNAc-pentapeptide translocase 
(MraY), thus forming lipid I (C55-PP-MurNAc-pentapeptide). In this step, the MraY-
catalyzed reaction can be targeted by tunicamycin, which belongs to the uridyl 
peptide antibiotic family 
[ 109 ]
. Tunicamycin causes competitive and reversible 
inhibition for the MraY substrate but does not affect the rate of polyprenyl phosphate 
binding 
[110]
. Besides, C55-P plays a crucial role in membrane-associated biosynthesis 
steps and cell wall teichoic acid biosynthesis as well as supports polysaccharide 
transport across the cytoplasmic membrane in the later step. Therefore, blocking this 
lipid carrier could inhibit PGN synthesis. The lipopeptide antibiotic amphomycin 
binds to the substrate of C55-P for the inhibition of this step 
[111,112]
. 
ix) Formation and translocation of lipid II. Another UDP-GlcNAc is linked to the 
MurNAc moiety of lipid I to form lipid II (C55-PP-GlcNAc-MurNAc-pentapeptide) 
by the membrane-associated transferase MurG. After further modification, the newly 
synthesized lipid II is translocated across the cytoplasmic membrane for the final 
PGN assembly. Two protein transporters, FtsW and MurJ, are responsible for the 
translocation of lipid II across the membrane 
[113]
. Of all the molecules involved in 
cell wall biosynthesis, lipid II, the key building block of PGN biosynthesis, is 
undoubtedly the most directly targeted molecule by several classes of antibiotics. In 
this stage, some lantibiotics function via multiple mechanisms, such as by binding to 
lipid II, disrupting membrane integrity through pore formation, or blocking 
transglycosylation 
[114]
. After flipping of lipid II to the outside of the cytoplasmic 
membrane, the glycopeptide moiety of lipid II is released and linked to an existing 
substrate strand of PGN by transglycosylase. Moenomycin, a glycolipid antibiotic, 
binds and inactivates this enzyme inhibiting this step of PGN synthesis 
[115,116]
.  
v) Covalent cross-linking of PGN strands. Adjacent PGN strands are cross-linked to 
form the final polymer on the extracellular side of bacterial cells. This process is 
catalyzed by PBPs, which catalyze both transglycosylation reactions of the 
disaccharide units MurNAc-GlcNAc and transpeptidation (cross-linking) of PGN 
peptides 
[117]
. The latter reaction leads to the formation of the interpeptide bridges 
between the D-Ala–D-Ala residues of peptide chains and the pentaglycine residues. 
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The D-Ala at the C-terminal end of the pentapeptide is removed in the process 
[51]
. 
This enzymatic reaction is the target of the glycopeptide antibiotic vancomycin, 
which binds to the D-Ala–D-Ala residues of PGN strands, thereby inhibiting the 
transglycosylation and transpeptidation reactions 
[118 ,119]
. These reactions are also 
inhibited by penicillin, ampicillin, and other β-lactam antibiotics, which bind to the 
transpeptidase active site of PBPs by mimicking the structure of D-Ala–D-Ala residue 
of the PG pentapeptide 
[120]
.  
vi) Recycling of the lipid carrier C55-P. C55-P is converted back to its pyrophosphatase 
from C55-PP, which is released by the transglycosylase reaction, and then flipped back 
across the membrane to repeat the C55-P-mediated transport cycle 
[121]
. Bacitracin 
retains C55-PP outside the bacterial membrane, thus inhibiting the function of this 
lipid carrier and the subsequent PGN synthesis 
[122,123]
.  
1.4.2.2 Action mechanism of DAP 
DAP with its distinctive structure shows effective bactericidal activity against most 
gram-positive bacteria 
[ 124 ]
. Nevertheless, the precise biological mechanism 
underlying DAP action remains poorly understood. Several studies have reported 
different action mechanisms of DAP, and many research groups have attempted to 
elucidate these proposals. Briefly, the main proposed action modes can be categorized 
into two major types: inhibition of cell wall macromolecule synthesis (specifically 
PGN and LTA), and interference with the normal membrane function. 
Inhibition of PGN or/and LTA synthesis  
In Chapter 1.2 and 1.4.2.1, we have depicted the complex pathway of PGN 
biosynthesis. Several early studies have reported the inhibition of PGN formation by 
DAP. Allen and colleagues first proposed that DAP could inhibit PGN biosynthesis in 
S. aureus. They showed that DAP inhibited the formation of the PGN precursor, 
UDP-MurNAc-pentapeptide 
[125]
. However, they later observed an inhibition of LTA 
biosynthesis and suggested this pathway as the target of DAP 
[126 ]
. Boaretti and 
colleagues reported that DAP binds irreversibly to the bacterial cell membrane, 
suggesting that DAP cannot be involved in the synthesis of PGN precursor molecules 
in the cytoplasm 
[127]
. They also claimed that LTA is the primary target for DAP 
[128]
. 
However, the hypothetical inhibition of LTA biosynthesis was not consented by 
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Laganas and colleagues 
[129]
. Their investigation suggested that LTA biosynthesis was 
not the primary target. Later, they also identified the effect of DAP on growth-
arrested cells, in which all the macromolecular biosynthesis pathways were blocked. 
Their results showed that DAP inhibited all macromolecular synthesis in S. aureus, 
Enterococcus faecalis, and Enterococcus hirae without kinetic or dose specificity for 
LTA. DAP remained bactericidal in the absence of ongoing LTA synthesis. Hence, 
the bactericidal activity of DAP does not occur via inhibition of LTA synthesis in 
these pathogens. 
Interference with normal membrane function  
Many researchers believe that DAP functions primarily by disturbing the normal 
membrane function of the bacterial cell. Silverman et al. used fluorimetric and flow 
cytometric assays to demonstrate that DAP exerts rapid bactericidal activity in 
association with the dissipation of the cell membrane potential 
[75]
. Cotroneo and 
colleagues suggested that DAP might promote the formation of small and discrete 
pores in the cell membrane of S. aureus 
[130]
. They also showed that DAP altered the 
cell wall morphology by abnormal septation events. Furthermore, Pogliano and 
colleagues reported the colocalization of DAP-induced curved membrane patches and 
the bacterial protein DivIVA, which is involved in cell wall synthesis via recruitment 
of other cell division enzymes, thus demonstrating DAP-mediated alterations in cell 
morphology 
[131]
.  
Researchers at Cubist Pharmaceuticals Inc. suggested that it is indeed unclear whether 
DAP activity occurs via one fundamental mechanism 
[132]
. Collectively, although the 
exact mechanism underlying DAP action is under debate since many years, all these 
findings and the proposed action modes led to a general consensus and the currently 
accepted hypothesis that DAP effects its rapid bactericidal activity primarily by 
disrupting the normal cytoplasmic membrane function 
[133,134,135]
.  
The prevalent model for the mechanism of action involves a calcium-dependent 
insertion of the lipophilic tail of the DAP molecule into the bacterial target membrane 
without entering the cytoplasm of the cell 
[136]
. This mechanism is only effective 
against gram-positive bacteria because DAP is unable to penetrate the outer 
membrane of gram-negative bacteria 
[67]
. However, DAP may insert into the 
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membrane via two different mechanisms. The first hypothesis claims that calcium-
bound DAP forms oligomers on the bacterial cell membrane 
[75]
, whereas the other 
theory suggests that calcium-bound DAP oligomerizes to form loose micelles before 
insertion into the cell membrane 
[133]
. In the presence of calcium ions, insertion of 
DAP into the cell membrane is considered to generate an ion conducting channel and 
disrupt the functional integrity of the bacterial membrane, ultimately resulting in cell 
death. This mechanism is in agreement with both the hypothesis for cell membrane 
insertion.  
 
Figure 8: Hypothetical mechanisms of action of daptomycin (DAP) suggested by Silverman et al.. 
Step 1: DAP insertion into the cytoplasmic membrane in the presence of calcium; step 2: DAP 
oligomerization and disruption of the membrane; step 3: the efflux of potassium ions, membrane 
depolarization, and cell death. Picture adopted from Silverman et al., 2003 
[75]
. 
The hypothesis that calcium-bound DAP oligomers are formed on the bacterial cell 
membrane is illustrated in Fig. 8. It shows that DAP binds Ca
2+ 
and then inserts into 
the bacterial membrane headgroups in the first step. During this step, the presence of 
calcium induces a conformational change in DAP to increase its amphipathicity and 
to increase its interaction with neutral or acidic membranes 
[ 137 ]
. Then DAP 
oligomerizes in the membrane, thus disturbing membrane integrity. This is followed 
by rapid membrane depolarization and intracellular potassium ion leakage, which 
subsequently causes cell death due to the widespread cessation of DNA, RNA, and 
protein synthesis. Notably, DAP treatment does not cause cell lysis in S. aureus, 
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suggesting that this hypothesis does not depend on cell lysis 
[130]
. Furthermore, large 
molecules are not released from the cytoplasm 
[138]
.  
 
Figure 9: Hypothetical mechanism of action of daptomycin (DAP) suggested by Robbel et al.. 
DAP forms micelles after addition of Ca
2+
 in the solution. The complex approaches the membrane 
and dissociates in close proximity of the lipid bilayer. DAP subsequently inserts into the 
membrane, ultimately leading to cell death. Picture adopted from Robbel et al., 2010 
[76]
. 
The second hypothesis, mostly based on nuclear magnetic resonance (NMR) studies 
[133,137,139]
, states that DAP forms micelles with 14-16 subunits in the presence of a 
minimum of 1:1 calcium to DAP molar ratio in solution to become competent for 
membrane insertion (Fig. 9). These micelles are vehicles to deliver DAP to bacterial 
cell membranes at high local concentrations. To enable interaction with the bacterial 
membrane, the micellar DAP structure dissociates and individual DAP molecules are 
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inserted into the membrane. This insertion is facilitated by calcium, which binds 
strongly to the PG headgroups, and may be accompanied by a second conformational 
transition to generate larger pores 
[137]
. In the final step, potassium efflux and 
membrane depolarization, lead to cell death.  
 
Figure 10: Hypothetical mechanisms of action of daptomycin (DAP) suggested by Müller et al.. 
(A) Peripheral membrane proteins MurG and PlsX localize to regions of increased fluidity (RIFs) 
indicated by a high concentration of fluid lipids (red). (B) DAP inserts into such regions and 
induces bilayer distortions. (C) DAP forms oligomer on the membrane stimulated by calcium ions. 
More fluid lipids are attracted. DAP molecules flip through the bilayer to the inner leaflet, causing 
membrane proteins to be displaced from the RIFs. (D) DAP blocks access to fluid lipids in the 
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inner leaflet, thus increasing membrane rigidity. Picture adopted from Müller et al., 2016 
[140]
. 
In addition to these two main mechanisms underlying DAP bactericidal activity, 
Müller and colleagues recently proposed a new DAP action mechanism involving 
inhibition of cell envelope synthesis by interfering with fluid membrane 
microdomains 
[140]
. Using the model organism Bacillus subtilis and different assays, 
including proteomics, ionomics, and fluorescence light microscopy, they revealed that 
DAP does not lead to membrane pore formation or rapid K
+
 leakage and membrane 
curvature, but acts on the cell membrane by causing the clustering of fluid lipids, 
which in turn increases membrane rigidity and causes delocalization of the peripheral 
membrane proteins MurG and PlsX, which are involved in PGN and phospholipid 
synthesis. The novel DAP action mechanism proposed on the basis of these findings 
is shown in Fig. 10. Once DAP reaches the bacterial cell membrane, it inserts its short 
lipid tail between the fatty acyl chains of phospholipid molecules, and its large 
peptide ring structure causes strong disturbance in the regular fatty acid packing of the 
cell membrane. Ca
2+
-dependent DAP oligomerization leads to further distortion of the 
membrane bilayer. Owing to its bulky structure, DAP localizes to the regions of 
increased fluidity (RIFs) and restricts the chain flexibility of lipids. Moreover, DAP 
has been shown to flip from one membrane leaflet to the other. Therefore, DAP has a 
dramatic effect on the fluid lipid order/disorder balance of the bacterial cell 
membrane.  
1.4.2.3 The function and effect of Ca
2+
 and lipids 
Although many aspects of DAP mechanism are subject to an ongoing debate, all the 
studies are consistent with the notion that the antibacterial activity of DAP is 
dependent on the presence of calcium ions (Ca
2+
) 
[141,142]
. The DAP molecule is an 
anionic molecule with one basic and four acidic amino acids. After binding to Ca
2+
, 
the Ca
2+
-DAP complex can act as a cationic peptide and interact with negatively 
charged phospholipids by an electrostatic attraction 
[135]
. Ca
2+
 neutralizes the negative 
charges of the DAP molecule and the anionic phospholipid heads (e.g., PG) of the cell 
membrane to promote the membrane insertion, and bridges the gap between them 
[137,143]
. Moreover, investigations based on NMR and CD showed that the presence of 
Ca
2+
 leads to oligomerization and micelle formation 
[144,145]
. Other divalent cations 
may enable the insertion of DAP into membrane bilayers; however, studies have 
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demonstrated that Ca
2+
 can bind better and stronger to DAP, compared to other 
divalent cations such as Mn
2+
, Mg
2+
, Cu
2+
, and Ni
2+
 
[139,146]
. 
In addition to calcium, lipids, especially those with negatively charged headgroups, 
are also critical for the interaction between DAP and lipid membranes. Lipid 
compositions of bacterial membranes are highly variable; however, PG, CL, and PE 
generally account for a large portion of the phospholipids of bacterial membranes.  
The rapid activity of DAP on bacterial membranes has been investigated in numerous 
studies with both cells and artificial model membranes. Early studies using artificial 
model membranes supplemented with PC, and sometimes cholesterol, have shown 
that in the presence of Ca
2+
, DAP can act spontaneously on the lipid bilayer in the 
absence of any bacterial protein or other cell surface components 
[147,148]
. However, 
CD spectroscopy demonstrated that the effect of DAP is considerably lower when 
binding to pure PC membranes, whereas profound conformation changes occur in 
membranes containing both PC and PG 
[137]
. Because PG and CL are abundant 
anionic phospholipids present in bacterial membranes, their depletion could reduce 
the net negative charge of the membrane, thus affecting the function of DAP
 [149]
. The 
key role of PG in DAP action is also supported by studies with bacterial cells. 
Fluorescently labeled daptomycin-Ca
2+
 complexes interact preferentially with PG-
enriched membrane regions in B. subtilis cells 
[ 150 ]
. Furthermore, changes in 
membrane lipids and fluidity have been demonstrated to affect the DAP susceptibility 
[151 ,152 ]
. For instance, an MRSA strain with increased carotenoid production was 
reported to show reduced susceptibility against DAP and other cationic antimicrobial 
peptides 
[153]
. Moreover, many of the mutations that alter cell membrane composition 
have been shown to prominently affect the susceptibility to DAP
 [150]
. S. aureus, for 
example, is one of the susceptible bacterial species containing large amounts of PG in 
their cell membrane, and mutations that decrease the amount of PG result in the 
reduced susceptibility 
[154,155]
. In addition, PG is the immediate precursor of CL, 
which has been demonstrated to cause more active membrane binding of DAP with 
around 10% content in model membranes 
[156]
. Although several lines of evidence 
show the involvement of CL in the interaction of DAP and bacterial membrane, its 
precise role in the action mechanism is not well defined. For example, Zhang and 
coworkers reported that CL inhibits membrane permeabilization in the liposome 
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model, and they claimed that CL might mediate DAP resistance by competing for it 
with PG 
[156]
. Tran et al. also provided the evidence to support a similar effect in vivo 
[157]
.  
Despite significant evidence of DAP activity against the cell membrane in susceptible 
bacteria, the cell wall has also been considered a target site of DAP
 [158 ,159]
. As 
described in Chapter 1.2 and 1.3.2, cell membranes are involved in PGN synthesis 
and C55-P is a key lipid carrier that anchors in the membrane. It can be bound with 
antibiotics like fruilimicin and MX-2401 
[160,161]
. As DAP is structurally related to 
fruilimicin and MX-2401, it can bind to C55-P, resulting in the inhibition of PGN 
synthesis 
[162,163]
. 
1.4.3 Resistance against antibiotics 
1.4.3.1 Role of antibiotics resistance 
With the development and widespread use and misuse of antibiotics, several bacterial 
species of human and animal origin have developed numerous mechanisms for 
resistance to an increasing number of antibiotics 
[164,165,166]
. Such bacterial resistance 
should be a concern for many reasons. First, the increase in antibiotic resistance is 
closely associated with the use of antimicrobial agents in clinical practice. For 
example, a microorganism/bacterium might be initially sensitive to one 
antimicrobial/antibacterial agent but can later adapt gradually and develop resistance 
to these type of agents. The extensive use of antibiotics in clinical practice is causing 
an increase in resistant bacteria. Bacterial resistance can limit treatment options, 
compromise effective therapy, and subsequently result in treatment failure 
[167,168]
. In 
addition, with the continued use of various antibiotics in prolonged therapy, 
microorganisms could develop resistance mechanisms to multiple drugs (multidrug 
resistance) 
[ 169 ]
. Multiple resistance mechanisms, which are hard to control and 
complicate the treatment, are becoming the norm and increase both human morbidity 
and financial costs in hospitals 
[170,171]
. Finally, the spread of resistant bacteria is 
another noticeable problem, especially for infection control within healthcare 
institutions and other communities 
[172,173]
. Antimicrobial resistance has resulted in an 
enormous clinical and financial burden on health care systems, and has undoubtedly 
become a global health concern 
[174,175]
. 
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A complete understanding of the molecular mechanisms of antibiotic resistance 
would allow us to develop new approaches and control strategies to further reduce the 
spread of resistant bacteria and their evolution and may eventually enable to 
overcome most of the antibiotic resistance in the health care system. 
Many excellent reviews describe antibiotic discovery, modes of action, and 
mechanisms of resistance over the past decades 
[176,177,178]
. With the evolvement of 
bacterial resistance to antibiotics, new resistance mechanisms are constantly being 
described. Although a wide range of biochemical and physiological mechanisms may 
be involved in resistance and the manner of acquisition of resistance may vary among 
bacterial species, the main and classic antibiotic resistance mechanisms in bacteria are 
summarized in Fig. 11. 
 
Figure 11: Biochemical and genetic aspects of antibiotic resistance mechanisms in bacteria. 
Picture adopted from Senka et al., 2008 
[179]
. 
1.4.3.2 Mechanisms of DAP resistance 
DAP is a calcium-dependent cyclic lipopeptide antibiotic with potent bactericidal 
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activity in vitro against a wide variety of clinically important gram-positive bacteria, 
including multidrug-resistant organisms, such as MRSA, penicillin-resistant 
Streptococcus pneumoniae, glycopeptide-intermediate S. aureus, coagulase-negative 
staphylococci, and vancomycin-intermediate S. aureus (VISA) 
[64,65,180]
. DAP also 
maintains clinical activity for the treatment of infections caused by vancomycin-
resistant enterococci (VRE) 
[181,182]
.  
Although most gram-positive bacteria are susceptible to DAP, several studies have 
reported the emergence of DAP-resistance (DAPr) strains during prolonged treatment 
in several important gram-positive bacteria, such as S. aureus, Enterococcus faecalis, 
and Enterococcus faecium 
[183,184]
. These strains with reduced susceptibility to DAP 
could consequently lead to clinical treatment failures; thus, it is important to 
understand the mechanism of DAP resistance to reduce its occurrence and enhance 
the understanding of the mechanism of interaction between DAP and its target. 
Moreover, the clinical failures caused by DAPr have also been mentioned during 
treatment for vancomycin resistant Enterococcus faecium 
[185]
, vancomycin resistant 
Enterococcus faecalis 
[186]
 and Enterococcus durans 
[187]
. On the basis of phenotypic 
observations and DNA sequencing, several research groups have proposed to 
elucidate the mechanisms of DAP resistance in bacteria. Serial passages with 
increasing concentration of DAP rarely led to resistance in the strains of 
staphylococci, enterococci, and pneumococci [
188 ]. Moreover, experiments with 
chemical-induced mutagenesis did not show any resistance [154]. Some phenotypes 
associated with DAPr, such as thickened cell walls, enhanced surface charge, changes 
in cell membrane fluidity and phospholipid synthesis, cross-resistance to host defense 
cationic peptides, have been identified by many research groups 
[152]
. Although the 
mechanisms seem to be diverse, complex, and are not yet completely defined, the 
studies have provided important insights and shown that bacterial resistance is related 
to activation of the inherent bacterial self-defense processes and adaptation in cell 
wall homeostasis and membrane phospholipid metabolism 
[189,190]
. Genomic studies 
have demonstrated the involvement of single point mutations in increasing DAP 
resistance in S. aureus
 [ 191 ]
. Laboratory studies have identified several mutations 
associated with reduced susceptibility in several genes, such as mprF, yycG, rpoC, 
and rpoB.  
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The mprF (multiple peptide resistance factor) gene was found by transposition 
mutagenesis in many resistant S. aureus strains 
[154]
. This gene encodes the 
bifunctional membrane enzyme MprF (also known as phosphatidylglycerol 
lysyltransferase) that couples lysine to PG to form lysyl-phosphatidylglycerol (LPG) 
using lysyl-tRNA as a co-substrate in the inner leaflet of the membrane, and it also 
provides translocase activity to subsequently transfer LPG to the outer membrane 
leaflet 
[192]
. The mutant enzyme found in resistant strains showed gain-in-function that 
led to an increase in the LPG content and the acceleration of its flipping 
[193]
. As LPG 
is positively charged, it was considered to be a major contributor of the alteration of 
surface charge that results in the reduction of the binding sites for the Ca
2+
-bound 
DAP in bacterial membranes 
[ 194 ]
. The mprF deletion mutants showed increased 
susceptibility to DAP and other CAMPs 
[195,196]
, whereas an insertion in the mprF 
gene resulted in increased susceptibility to cationic peptides in S. aureus 
[197]
.  
The yycFG gene encodes the YycFG response regulator system, which is a critical 
two-component regulatory system for cell wall metabolism and biofilm formation 
[198]
. 
YycFG mutations have been reported in many DAPr strains 
[154,199]
. Studies in S. 
aureus have shown that enhanced expression of YycFG leads to increased PGN 
biosynthesis whereas its depletion results in cell death 
[200]
. 
The rpoC and rpoB genes encode RNA polymerases 
[154]
. The effect of mutations in 
rpoB and rpoC on DAP susceptibility is not completely clear; however, alterations in 
both RpoB and RpoC have been implicated in increased DAP minimal inhibitory 
concentration (MIC) via serial passage experiments 
[154]
. Whole-genome sequencing 
studies confirmed that hetero-VISA strains with rpoB mutations showed reduced 
susceptibility to DAP, compared to that observed in the parent MRSA strain. 
Moreover, rpoB mutation-induced resistance was accompanied by thickening of the 
cell wall and reduction of the cell surface negative charge 
[201]
. Besides, Watanabe and 
coworkers indicated that rpoB mutation is one of the main contributors to vancomycin 
resistance in S. aureus 
[202]
. Therefore, although rpoB is not a regulator gene, its 
mutation changes the transcription profile of the cell drastically, compared to that by 
other regulatory mutations 
[203,204]
.  
The three components of the LiaFSR system are a transmembrane protein (LiaF), 
which is encoded by liaF and acts as a specific inhibitor of LiaR-dependent gene 
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expression 
[205]
; a membrane bound bifunctional histidine-kinase (LiaS), which acts as 
a phosphatase in uninduced conditions and prevents LiaR phosphorylation to maintain 
the system in the “off” state [206]; and a response regulator (LiaR), which regulates the 
expression of a gene cluster (liaIHGFSR) that is involved in cell membrane stress 
response against attack by antibiotics and antimicrobial peptides 
[150,207]
. The studies 
in B. subtilis showed that the membrane-anchored LiaF could negatively regulate the 
LiaRS system 
[205]
, hence, it is predicted that liaF mutations may reverse the 
inhibitory effect of LiaS, thus activating the LiaFSR system. The activation of this 
system may influence cell-envelope homeostasis by affecting the transcription of 
several genes that can help mitigate the damage caused by an antibiotic. For instance, 
this system is activated by DAP, which in turn reduces bacterial DAP susceptibility 
[150,163]
. 
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2. Aims of the thesis 
DAP is a reliable antibiotic in the combat against clinical pathogens, as it displays 
strong bactericidal activity against high inoculum MRSA resulting in rapid cell death. 
Nevertheless, the precise mechanism of DAP action remains controversial. Despite 
different views, all the studies suggest that cell membrane and Ca
2+
 are involved in 
DAP action mechanism. Understanding the precise DAP mechanism requires an 
understanding of the target of DAP. It is therefore essential to study the binding 
behavior of DAP and to define its target binding site in bacterial membranes. 
Furthermore, this knowledge may help to elucidate the precise mode action of DAP as 
well as suggest approaches to reduce bacterial DAP resistance in clinical use. 
The primary goal of this thesis was to gain more insights into the bactericidal 
mechanism of action of DAP using different types of fluorescence imaging techniques. 
Therefore, this research focused on the following objectives: 
1. Investigation of the binding behavior of DAP to S. aureus cells using highly 
inclined and laminated optical sheet (HILO) microscopy. A fluorescent derivative, 
5(6)-TAMRA-X, SE-labeled DAP (DAP-TMR) that retains antimicrobial activity 
was used for imaging. Additionally, the super resolution imaging method termed 
universal point accumulation imaging in the nanoscale topography (uPAINT) was 
used to study the binding of DAP to S. aureus at the single-molecule level. 
2. Examination of the colocalization of DAP-TMR with the cell division protein 
FtsW and lipid II. Dual-color imaging was used to acquire images from two 
fluorescence channels. FtsW was expressed as a GFP fusion protein (FtsW-GFP) 
and nascent lipid II was labeled using BODIPY FL fluorescent vancomycin (Van-
BDP FL).  
3. Study of the specific interaction of DAP with selected lipid components. Fluid 
supported lipid bilayers, which were prepared on coverslips by fusion of very 
small unilamellar vesicles (VSUVs), were used to study the binding behavior of 
DAP dependent on the lipid composition of the membrane. PG and/or the 
bactoprenol lipids (C55-P, C55-PP, and lipid II) were integrated into neutral DOPC 
bilayers for investigating the specific binding of DAP. In addition, fruilimicin, 
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bacitracin, and oritavancin, which can specifically bind to C55-P, C55-PP, and lipid 
II respectively, were used to evaluate the specificity of DAP binding. 
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3. Materials and methods  
3.1 Bacteria 
3.1.1 Bacterial strains, media and growth conditions 
The S. aureus strain used in this thesis was the MSSA strain RN4200. To study the 
colocalization of DAP with a cell division protein, we constructed S. aureus RN4220 
strains expressing a C-terminal GFP fusion to FtsW by modifying its native 
chromosomal locus. Both strains were kindly provided by Dr. Fabian Grein from 
the Institute for Pharmaceutical Microbiology, University Hospital Bonn. 
Glycerol stocks were used for long-term storage of the bacterial strains. An overnight 
culture was mixed 1:1 with sterile glycerol (v/v) and stored at -80 °C. Prior to each 
experiment, the frozen bacterial strains were revived by streaking out on solid agar 
plates and incubating overnight at 37 °C.  
Unless otherwise noted, S. aureus were cultured either in Luria Bertani (LB) medium 
or in tryptic soy broth (TSB) at 37 °C with gentle agitation. The formula of the LB 
medium is described in Table 1. For growth experiments, cells were grown in LB 
medium at 37 °C until an optical density at 600 nm (OD600) of 0.3 was reached; these 
cells were used in the subsequent steps. 
Table 1. The formula of the Luria Bertani medium 
1 % NaCl 5.0 g 
1 % tryptone 10.0 g 
0.5 % yeast extract 5.0 g 
dH2O added to1 L 
For agar plates 17 g agar per 1 L medium 
3.1.2 Sterilization of media, equipment, and bacterial cultures 
The maintenance of sterile conditions is necessary to work safely with bacterial 
samples.  
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Heat-stable culture media, solutions, buffers, plastic vials, and pipette tips were 
sterilized in a steam autoclave (Labortechnik AG, Oberschleißheim, Germany) at 
121 °C for 20 min. Heat-sensitive solutions were filtered using cellulose acetate 
membrane filters (Millipore, Renner, Darmstadt, Germany). Glassware was incubated 
in a sterilizator (Kelvitron
®
 T; Heraeus, Langenselbold, Germany) at 180 °C for 4 h. 
Bacterial cultures and contaminated labware were autoclaved at 134 °C for 30 min. 
3.1.3 Measurement of optical density of liquid cultures 
The cell density of bacterial suspensions was determined by measuring OD600 using a 
spectrophotometer, against the respective suspending medium as a blank. 
3.1.4 Determination of the MIC of DAP  
MIC is defined as the lowest antibiotic concentration that prevents visible turbidity 
after 18 h of incubation at 37 °C. MIC was determines using 96-well polypropylene 
microtiter plates (TPP, Techno Plastic Products AG, Switzerland) containing    
LB medium supplemented with 1 mM CaCl2 in a standard serial dilution assay accord 
-ing to the broth microdilution guidelines established by the Clinical and Laboratory 
Standards Institute (CLSI) 
[208]
. A culture of S. aureus was grown to an OD600 of 1 
and subsequently diluted to 1 × 10
5
 cells/mL. Then, 50 μL of the bacterial suspension 
was mixed with 50 μL of DAP in LB medium (serial dilutions were performed to 
obtain 20, 15, 10, 5, 3, 2, 1.5, 1, 0.5, 0.25 μM solutions). The inoculated microtiter 
plate was incubated for 10 min at room temperature (RT) on a microtiter shaker 
(Titertek; Flow Laboratories, Germany). Positive controls contained 50 µL of 
inoculum and 50 µL of LB medium without antibiotic. The MIC was determined after 
18 h of incubation at 37 °C without agitation. The results were recorded as mean 
values of at least two independent experiments performed in duplicate. CaCl2 was 
added to all cultures to a final concentration of 1 mM, unless indicated otherwise. 
3.1.5 Effect of Ca
2+
 on DAP activity   
A culture of S. aureus was grown overnight in LB medium-containing flask at 37 °C 
on a rotating shaker at 250 rpm. The culture was then diluted 250-fold using fresh LB 
medium and incubated at 37 °C to an OD600 of 0.3. From this, aliquots were diluted 
1000-fold using fresh LB medium in 250-mL flasks supplemented with: 1) no 
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antibiotic (control), 2) 2 µM DAP and 1 mM Ca
2+
, 3) 0.5 mM DAP and 1 mM Ca
2+
, 
4) 2 µM DAP and 0.1 mM Ca
2+
, 5) 2 µM DAP and 0.1 mM EDTA. Then samples 
were incubated at 37 °C with shaking at 250 rpm. The OD600 was measured during 
cell growth at every 30-min interval for a total period of 210 min. 
3.2 Reagents 
3.2.1 Chemicals and solvents 
The reagents and chemicals used in this work and their respective suppliers are listed 
in Table 2. All the chemicals were of analytical grade or better. 
Table 2. Chemicals and solvents used in this study 
Chemical/Solvent  Manufacturer 
BODIPY FL NHS ester  Lumiprobe 
5(6) - TAMRA - X, SE  AnaSpec 
Alexa fluor 546 Invitrogen 
Nile red  Sigma-Aldrich 
Agarose  Merck 
Agarose low melt Applichen 
Agar Invitrogen 
Diethylether Merck 
Triton X-100 Merck 
D-Serine Sigma-Aldrich 
Calcium chloride  Carl Roth 
Zinc chloride Carl Roth 
Sodium chloride Sigma-Aldrich 
β-Cyclodextrin  Sigma-Aldrich 
Glycerol  ICN Biomedicals Inc 
Sodium hydroxide Merck 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Methanol Merck 
Ammonium Hydroxide Sigma-Aldrich 
Chloroform Merck 
Dimethylformamide (DMF) Merck 
Ethylene glycol-bis(2-aminoethylether)- Sigma-Aldrich 
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N,N,N′,N′-tetraacetic acid (EGTA) 
Tryptone  Sigma-Aldrich 
Yeast extract Carl Roth 
Tween-80 Calbiochem 
Hellmanex II Hellma 
Sulfuric acid Merck 
Hydrogen peroxide Sigma-Aldrich 
Tryptone soya broth Thermo Scientific 
3.2.2 Antibiotics 
When required, the appropriate antibiotic(s) was (were) added to either growth 
medium or solutions listed in Table 3. DAP, friulimicin and bacitracin were dissolved 
in sterile water. Oritavancin was dissolved and diluted in the presence of 0.002% 
Tween-80 (vol/vol). The solutions were filter-sterilized, aliquoted and stored at             
-20 °C. 
Table 3. Antibiotics used in this study 
Antibiotic Supplier / Source 
Daptomycin Novartis 
Vancomycin-BODIPY FL Molecular Probes 
Friulimicin University of Bonn, AG Sahl 
Bacitracin University of Bonn, AG Sahl 
Oritavancin University of Bonn, AG Sahl 
3.2.2.1 Labeling of DAP 
DAP was fluorescently labeled by coupling 5(6)-TAMRA-X, SE or BODIPY FL 
NHS ester to the amino group of DAP (Fig. 12). DAP was dissolved in 
dimethylformamide (DMF) to obtain a 3 mM stock solution and stored at -20 °C. 
5(6)-TAMRA-X, SE and BODIPY FL NHS ester were dissolved in DMSO at a 
concentration of 16 mM and 26 mM, respectively. Then, 1.5 µL of 5(6)-TAMRA-X, 
SE or BODIPY FL NHS ester were added per 10 µL of DAP stock solution and 
incubated for 1 h at room temperature with gentle agitation. After incubation, 100 µL 
of ice-cold diethyl ether was added to the mixture, and the mixture was immediately 
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incubated on ice to enable precipitation. After 3-5 minutes, precipitates were observed 
at the bottom of the tube; then, the mixture was centrifuged at 13000 rpm for 5 min. 
The supernatant was carefully removed, the tube was rested for ~5 minutes to allow 
evaporation of the remaining ether, and the pellet was resuspended in methanol. 
Labeled and non-labeled DAP were separated by preparative thin-layer 
chromatography (TLC) using Rick solvent (chloroform/methanol/Aqua 
dest./ammonium hydroxide [88:48:10:1 (v/v)]). The bands corresponding to the 
labeled DAP were scratched from the TLC plates (Fig. 13), then extracted from the 
silica using distilled water.  
 
 
Figure 12: Structures of fluorescently labeled daptomycin (DAP) derivatives used in this study. 
The ornithine residue has a single free amino group, which was labeled with the fluorophores 
5(6)-TAMRA-X, SE or BODIPY FL NHS ester to form DAP-TMR and DAP-BDP FL, 
respectively. 
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Figure 13: Photograph of a thin-layer chromatographic purification of 5(6)-TAMRA-X, SE-
labeled daptomycin (DAP-TMR). The plate was illuminated by a UV lamp in order to visualize 
the DAP band duo to the intrinsic fluorescence of kynurenine residue.  
3.2.2.2 Antibacterial activity testing for DAP-TMR and BODIPY FL-labeled 
DAP 
DAP-TMR and BODIPY FL-labeled DAP (DAP-BDP FL) were tested for their 
antibacterial activity by broth dilution assays as described in section 3.1.4. Serially 
diluted labeled DAP solutions (20, 15, 10, 8, 5, 3, 2, 1.5, 1 and 0.5 μM) with 1 mM 
calcium in LB broth were tested. Growth inhibition was evaluated visually by 
turbidity. Growth controls without the antibiotic were prepared for comparison.  
3.2.2.3 Van-FL labeling of S. aureus 
A BODIPY FL conjugate of vancomycin (Van-BDP FL) was used to label cell walls 
of S. aureus. A culture of S. aureus RN4200 was grown overnight in tryptone soy 
broth (TSB) containing 0.125 M of D-serine 
[ 209 ]
. For fresh culture, 20 µL the 
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overnight culture was added to 5 mL TSB and 0.125 M D-serine, yielding a 1/250 
dilution, and the culture grown to an OD600 of 0.25. Cells were then washed and 
resuspended in the same volume of pure TSB medium, and incubated for 5 min at 
room temperature to allow D-Ala incorporation into the cell wall. Cells were then 
incubated with 2 µM Van-BDP FL for not longer than 5 min. The cells were washed 
to remove excess Van-BDP FL and incubated with a mixture of 0.1 µM DAP-TMR 
and 1 µM unlabeled DAP in the presence of 1 mM Ca
2+
. Cells were washed again and 
immobilized on an agarose pad and observed by fluorescence microscopy. 
3.2.3 Lipids 
The phospholipids used in this study and their suppliers are listed in Table 4. All the 
lipids were dissolved in chloroform in phosphate-free tubes and stored at -20 °C.  
Table 4. Phospholipids 
Lipids Supplier / Source 
DOPC: 1,2-dioleoyl-sn-glycero-3-
phosphocholine; 18:1 phosphatidylcholine  
Avanti Polar Lipids, Alabaster, USA  
DOPG:  1,2-dioleoyl-sn-glycero-3-
[phosphor-rac(1-glycerol)] sodium  salt;  
18:1 phosphatidylglycerol   
Avanti Polar Lipids, Alabaster, USA  
TopFluor PC Avanti Polar Lipids, Alabaster, USA 
C55-P Larodan Fine Chemicals AB 
C55-PP  Larodan Fine Chemicals AB 
Lipid II University of Bonn, AG Sahl 
3.2.3.1 Preparation of fluid supported bilayers  
Fluid supported bilayers were prepared on coverslips by fusion of VSUVs (average 
diameters of 18-25 nm), which were generated by detergent extraction with 
cyclodextrin
 [210]
. Neutral DOPC was used as a matrix to which 0.1 mol% or 0.2 
mol% of PG or/and bactoprenol lipids (C55-P, C55-PP, and lipid II) respectively, were 
added. TopFluor PC was used to visualize lipid membranes by fluorescence 
microscopy and gauge the mobility of the supported lipid bilayers. Twelve types of 
bilayers with different lipid components were prepared in this work. The types and 
53 
 
the corresponding volumes obtained from their stock solutions are listed in Table 5. 
The preparation of fluid supported bilayers is described in the next section. 
Lipid vesicle preparation 
The lipids from chloroform stock solutions were mixed in the appropriate molar ratios 
in clean glass vials, and the solvent was removed under a nitrogen stream. For 
fluorescence recovery after photobleaching (FRAP) measurements, 0.1 mol% 
TopFluor PC was included prior to evaporation. The dried thin lipid film was 
resuspended in 2 mL Triton X-100-HEPES buffer (20 mM HEPES, 150 mM NaCl, 2 
mM Triton X-100). For vesicle preparation, 200 µL lipid detergent solution was 
thoroughly mixed with 200 µL of cyclodextrin-HEPES buffer (20 mM HEPES, 150 
mM NaCl, 4 mM cyclodextrin) by vortexing for 2 min. The vesicles were generally 
used within 1 h of preparation.  
Supported bilayer formation on glass  
The vesicle fusion method was used to spread VSUVs onto a glass coverslip to form 
homogeneous lipid bilayers; the bilayer formation occurs within a few minutes. Here, 
400 µL VSUV solutions were pipetted onto glass slides in a home-built chamber and 
incubated for 10 min. The samples were then gently rinsed at least 5 times by adding 
300 µL and taken away with the same amount HEPES buffer.  Great care was taken 
to prevent contact between the bilayer surface and air. 
 Prior to bilayer formation, the glass coverslips were cleaned using Piranha solution 
(5:1 v/v concentrated H2SO4: 30% H2O2) for 30 minutes and rinsed extensively in 
distilled water. The home-built chambers were cleaned by sonicating in a 2% 
Hellmanex (Hellma, Müllheim, Germany) solution for 30 min and rinsing extensively 
with fresh distilled water. The coverslips and chambers were dried under airflow. 
Table 5. The Lipid components used in the various bilayer preparations 
Number Components 
1.  DOPC 
2.  DOPC + 0.1 mol% DOPG 
3.  DOPC + 0.1 mol% C55-PP 
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4.  DOPC + 0.1 mol% C55-P 
5.  DOPC + 0.1 mol% lipid II 
6.  DOPC + 0.1 mol% DOPG + 0.1 mol% C55-PP 
7.  DOPC + 0.1 mol% DOPG + 0.1 mol% C55-P 
8.  DOPC + 0.1 mol% DOPG + 0.1 mol% lipid II 
9.  DOPC + 0.2 mol% DOPG 
10.  DOPC + 0.2 mol% C55-PP 
11.  DOPC + 0.2 mol% C55-P 
12.  DOPC + 0.2 mol% lipid II 
3.2.3.2 Inhibition of DAP binding by specific target molecules 
Bacitracin, fruilimicin, and oritavancin were used to treat the bilayers containing 0.1 
mol% DOPG + 0.1 mol% C55-PP, 0.1 mol% DOPG + 0.1 mol% C55-P, and 0.1 mol% 
DOPG + 0.1 mol% lipid II, respectively.  
Binding of each antibiotic to the corresponding bilayers was achieved by incubating 
300 nM antibiotic with the bilayer (approximate ratio was 100 antibiotic molecules: 1 
bactoprenol molecule) for 5 min. Notably, 0.5 mM Zn
2+ 
and a final concentration of 
0.002% Tween 80 (vol/vol) were presented for the treatment of Bacitracin and 
oritavancin, respectively.  
The excess unbound antibiotics were gently washed off by adding 300 µL and taken 
away with the same amount HEPES buffer. Great care was taken to prevent contact 
between the bilayer surface and air. 
3.3 Fluorescence imaging methods 
3.3.1 Fluorescence microscopy 
A culture of S. aureus was grown in LB medium at 37 °C to an OD600 of 0.25. Then, 
1-mL cell suspension was pipetted into each of the six Eppendorf centrifuge tubes, 
and the suspensions were centrifuged, washed with HEPES buffer, and resuspended 
in 1/10 of the starting volume. Then, 100 µL of the concentrated cell suspension in 
each tube was incubated with a mixture of 0.1 µM DAP-TMR and 0.5 µM non-
labeled DAP. The cells in the six tubes were incubated for 0.5, 5, 10, 15, 20, and 25 
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min, respectively. The excess unincorporated DAP-TMR and non-labeled DAP were 
removed by washing the cells in HEPES buffer immediately. A small aliquot (2 µL) 
of the treated cells was placed on an agarose pad (1% low-melting point agarose in 
sterile water). The inverted agarose pad was then placed in a microscopy chamber 
(MatTek, USA) and imaged immediately.  
In addition to 0.5 µM non-labeled DAP, cells were also treated with a mixture of 0.1 
µM DAP-TMR and 1 μM, 6 μM, and 10 μM non-labeled DAP, in the presence of 1 
mM Ca
2+
 and imaged in the same way. Furthermore, where required, the 
exponentially growing cells of S. aureus RN4220 were stained with the membrane 
dye Nile red (5 µM).  
Fluorescence microscopy was performed using HILO to image the binding of low 
amounts of DAP-TMR with reduced background fluorescence 
[211]
. The oblique 
illumination beam angle was adjusted by focusing the beams in the back focal plane 
of the objective and shifting laterally. The schematic of the optical setup is shown in 
Fig. 14. An inverted microscope was equipped with a 63× objective lens with a 
numerical aperture (NA) 1.46 (Zeiss, Jena, Germany) and a 4× magnifier (Carl Zeiss 
MicroImaging GmbH, Göttingen, Germany) onto an electron-multiplying charge-
coupled device (EMCCD) camera (iXon DU-897D; Andor Technology, Belfast, 
Northern Ireland); 2 × 2 binning during acquisition resulted in a pixel size of 127 nm. 
Images were obtained within 3 min after DAP addition and recorded using 
transmitted light as well as laser excitation at 532 nm emitted by a solid-state laser 
(LaNova50 Green, Lasos, Germany) for 5(6)-TAMRA-X, SE. Fluorescence was 
filtered using the appropriate notch filter (NF03-532E-25, Semrock, USA). 
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Figure 14: Schematics of the highly inclined and laminated optical sheet (HILO) microscopy 
optical setup. Picture adopted from Giannone et al. 
[211]
. 
3.3.2 Super-resolution imaging 
We used the uPAINT method to study the binding of DAP-BDP FL to S. aureus at the 
single-molecule level 
[211]
.  
S. aureus RN4220 was grown in LB medium to exponential phase (OD600 = 0.25) at 
37 °C. Cells were centrifuged, washed with HEPES buffer, and resuspended in 1/10 
of the starting volume. A small aliquot (2 µL) of cells was placed on an agarose pad 
(1% low-melting point agarose in sterile water). The inverted agarose pad was then 
placed in a microscopy chamber (MatTek), and the chamber was placed under 
microscope. Before imaging, a mixture of 1 nM DAP-BDP FL and 6 µM non-labeled 
DAP was added into the chamber. 
Super-resolution imaging techniques comprise a rapidly emerging new field of 
microscopy that enhances the spatial resolution of light microscopy, allowing the 
observation of biological processes at the molecular level. Various super-resolution 
imaging methods have been devised, and they can be further categorized as 
illumination-based methods such as stimulated emission by depletion (STED) 
fluorescence microscopy and single-molecule localization-based methods such as 
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stochastic optical reconstruction microscopy (STORM), photoactivated localization 
microscopy (PALM), and PAINT. uPAINT, one of the single-molecule localization 
based super-resolution methods, can be implemented on any wide-field fluorescence 
microscope operating in oblique illumination 
[212]
. uPAINT is based on real-time 
imaging of fluorescently labeled target biomolecules on the cell membrane at the 
single-molecule level 
[211]
. A low concentration of fluorescent ligands for the targets 
of interest is introduced in the extracellular medium to ensure that a constant number 
of membrane molecules is being labeled during a imaging sequence. Oblique 
illumination is critical, as it allows to image fluorescent ligands bound to the cell 
surface without exciting the molecules in the solution above (Fig. 15). Thus, the 
uPAINT method is ideally suited for studies of membrane-bound molecules.  
 
Figure 15: The principle of universal point accumulation imaging in the nanoscale topography 
(uPAINT). Low concentrations of labeled ligands are added to the cell medium. Non-illuminated 
dye molecules are displayed in pink, fluorescent ones in red, and photobleached ones in brown; 
the oblique illumination is marked in blue. 
uPAINT acquisitions were performed on an inverted microscope operated in the 
HILO mode (Fig. 14). The tilting angle between the sample and the illumination beam 
was set to 5° to obtain an illumination thickness of ~2 µm in the center of the field. It 
allowed the imaging of individual DAP-BDP FL molecules bound to the cell surface. 
The microscope was equipped with a 100× objective lens with an NA of 1.46. And a 
4× magnifier was inserted before an EMCCD camera; 2 × 2 binning during 
acquisition resulted in a pixel size of 80 nm. A built-in C-Focus
TM
 system (Mad City 
Labs Inc., USA) was used to eliminate any possible microscope focus drift over long 
data collection periods. 
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BDP FL dyes were excited by a 488-nm laser (Sapphire-100; Coherent, USA); the 
illumination intensity was adjusted to 1-3 kW/cm
2
. Fluorescence was filtered using 
the appropriate notch filter (NF03-488E-25, Semrock). Images were acquired with an 
integration time of 20 ms and EM gain of 280. Two-image stacks of 9,000 images 
were recorded for the first 3 min and the second (subsequent) 3 min after DAP 
addition. Images were reconstructed with the software thunderSTORM [213]. 
3.3.3 Dual color imaging 
We examined the colocalization of DAP-TMR with the cell division protein FtsW and 
lipid II by combining HILO microscopy with dual-color imaging. For this, we 
inserted a dual-emission image splitter (OptoSplit II; Cairn Research Ltd, Faversham, 
UK) in front of the camera (Fig. 16). 
S. aureus expressing FtsW-GFP were grown in LB medium to an OD of 0.25 at 37 °C. 
Cells were centrifuged, washed with HEPES buffer, and resuspended in 1/10 of the 
starting volume. Then, 100 µL of the concentrated cell suspension in each tube was 
incubated with a mixture of 0.1 µM DAP-TMR and 1 µM non-labeled DAP for 0.5 
min. Excess unincorporated DAP-TMR and non-labeled DAP were removed by 
washing the cells in HEPES buffer immediately. A small aliquot (2 µL) of the treated 
cells was placed on an agarose pad. The inverted agarose pad was then placed into a 
MatTek chamber and imaged with a microscope immediately. 
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Figure 16: Schematics of the dual-color imaging system. The OptoSplit II system was inserted in 
the light path between microscope and the electron-multiplying charge-coupled device (EMCCD; 
Schematic produced by Cairn Research). 
Fluorescence images were acquired using HILO microscopy. An inverted microscope 
was equipped with a 63× objective lens with an NA of 1.46. A 4× magnifier was 
inserted in front of an EMCCD camera (iXon X-1170; Andor Technology); 1×1 
binning during acquisition resulted in a pixel size of 63.5 nm. The OptoSplit II system 
was placed in the light path between the microscope and EMCCD to visualize the two 
color channels in two spectrally separated images on the camera. A dichroic mirror 
(FF509-FDi01-25x36; Semrock) and a band-pass emission filter (LP02-561RE-25, 
Semrock) were used to separate the emission channels. Image separation was adjusted 
such that the camera chip was fully illuminated and the two spectrally separated 
images covered equal areas. FtsW-GFP fusion proteins were excited by a 488 nm 
laser (Sapphire-100), and the TMR dyes were excited by a 532 nm laser (LaNova50 
Green, Lasos). Two laser lines were guided to an acousto-optical tunable filter 
(AOTF; nC 1001, Opto-Electronics, France). The AOTF selected laser lines and 
defined illumination durations and intensity. Fluorescence was filtered using the 
appropriate notch filters (NF03-488E-25 and NF03-532E-25; Semrock). 
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Z-stacks were acquired for the two fluorescence color channels. A step size of 50 nm 
was used for acquiring z-stacks and 61 images were acquired for each stack. This 
covered a distance of 3 µm, which is larger than the axial extension of the bacteria. µ-
Manager 
[214] 
was used as the main program to control most of the components in the 
setup, including lasers, AOTF, motorized and piezo stages, EMCCD camera, and 
shutters. 
3.3.4 Total internal reflection microscopy 
Binding of DAP-BDP FL to lipid bilayers was studied using total internal reflection 
fluorescence (TIRF) microscopy.  
TIRF microscopy is a wide-field microscopy technique that allows selective 
excitation of samples just near the coverslip, with a thickness of approximately 100 
nm. An evanescent field is produced by a light beam passing through the coverslip 
with a large incident angle, which must be larger than the critical angle to ensure total 
internal reflection (TIR) of the beam at the glass/medium interface. Such TIR 
generates a very thin electromagnetic field above the coverslip. The intensity of this 
field decays exponentially with an increase in the distance from the surface 
[215]
.  This 
field can illuminate fluorescent molecules near the surface while avoiding excitation 
of the surrounding bulk molecules present further in the liquid. Thus, TIRF 
microscopy provides better contrast and reduced background signal from surfaces. 
The thin volume of excitation near the coverslip makes this technique ideal for 
investigating supported lipid bilayers.  
TIRF microscopy was performed using an inverted microscope equipped with a 63× 
oil immersion objective lens with an NA 1.46. A 4× magnifier was placed in front of 
onto an EMCCD camera; 2 × 2 binning during data acquisition resulted in a pixel size 
of 127 nm. For fluorescence excitation, a 488 nm laser (Sapphire-100) was used for 
BDP FL, and the excitation light was blocked using a notch filter (NF03-488E-25).   
After the supported lipid bilayers were formed on glass coverslips in the custom-built 
chamber, 1 mM Ca
2+
 was added into the chamber and the bilayers were incubated for 
5 min. Then, a mixture of 50 nM DAP-BDP FL and 1 µM non-labeled DAP was 
added into the chamber and imaged within 2 min.  
61 
 
For each condition, data were collected from at least 20 different areas on the bilayers. 
Movies with 100 frames were recorded at a frame rate of 60 Hz within 2 min after 
DAP addition. 
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4. Results and Discussion 
4.1 DAP binding behavior on the membrane of S. aureus 
4.1.1 Susceptibility testing of native DAP and fluorescently labeled DAP 
derivatives 
The MIC of native DAP, which was determined by serial dilution, for the strain 
RN4200 used in this study was 1 μM. DAP-TMR and DAP-BDP FL, the two 
fluorescent derivatives of DAP, were shown to retain antimicrobial activity. Both of 
them are 3 to 5 times less active than the ummodified DAP. Their reduced activity 
may not be attributed to modification of the ornithine residue because DAP variants 
with N-acylated ornithine show only minor differences in MIC 
[216]
. Therefore, a 
mixture of labeled DAP and a varying concentration of unlabeled DAP was used in 
the subsequent fluorescence microscopy measurements.  
4.1.2 Effect of calcium on the bactericidal activity of DAP 
DAP has previously been described to inhibit bacterial growth by disrupting normal 
cell membrane or cell wall function. It has been clearly established that calcium ions 
are essential for the DAP activity against gram-positive bacteria 
[137,139]
 and that the 
activity is diminished in the presence of alternative divalent ions. The peptide moiety 
of DAP is anionic, and it has a net charge of -3 at pH 7. The calcium-DAP complex 
acts as a cationic peptide and approaches the cell membrane by an electrostatic 
interaction. To reconfirm the effect of Ca
2+
 on the activity of DAP against cultures of 
S. aureus, we compared the cell growth rates during DAP treatment with supra-MIC 
doses (2 μM) and sub-MIC doses (0.5 μM) in the presence of varying Ca2+ 
concentration: no Ca
2+
 (0.1 mM EDTA was used to chelate divalent cations in LB 
medium); physiological level of Ca
2+
 (1 mM); and low Ca
2+
 level (0.1 mM). The 
untreated culture was considered as control. Culture density (OD600) was measured 
periodically during DAP treatment.  
63 
 
 
Figure 17: Growth dependence of Staphylococcus aureus cells on the concentration of daptomycin 
and Ca
2+
. Cells were grown in the presence of different concentrations of DAP and Ca
2+
, and the 
growth was monitored by measuring the optical density at 600 nm (OD600). This is a qualitative 
test for verification only. 
Cells treated with a supra-MIC dose (2 µM) with 0.1 mM EDTA and sub-MIC dose 
(0.5 µM) with 1 mM Ca
2+ 
showed growth rates identical to those in the control, 
whereas cells treated with supra-MIC doses with insufficient concentration of Ca
2+ 
(0.1 mM) showed considerably slow growth. In contrast, the bacterial growth was 
completely inhibited under the treatment with supra-MIC doses with 1 mM Ca
2+
. 
These findings confirm that the bactericidal activity of DAP on S. aureus cultures is 
calcium-dependent. 
4.1.3 Fluorescence microscopy of S. aureus treated with DAP  
S. aureus is a gram-positive bacterium and a prominent pathogen in the community 
and healthcare settings, and is therefore widely used as a model organism. To 
investigate the binding behavior of DAP to S. aureus, we used DAP-TMR, 
fluorescently labeled DAP with antimicrobial activity. By using HILO microscopy, 
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we imaged the binding of low amounts of DAP-TMR to S. aureus cells with reduced 
background fluorescence.  
Cells were grown to exponential phase (OD600 = 0.25) in LB medium. One hundred 
microliters of cells were incubated with a mixture of 0.1 µM DAP-TMR and 
increasing concentrations of non-labeled DAP: sub-MIC (0.5 µM), in the range of 
MIC (1 µM), and supra-MIC (6 and 10 µM). The cells were imaged at different time 
points (0.5, 5, 10, 15, 20, and 25 min; Fig. 18). The same contrast settings were used 
for all images in Fig. 18A. However, to visualize the fluorescence distribution on cells 
at different times and concentrations, the contrast and brightness of each image was 
set to an optimal value in Fig. 18B.  
DAP-TMR accumulated at the cell membrane (Fig.18) and there were several 
noticeable findings: 1) cell intensity and cell size were considerably different after 
treatment with different concentrations of DAP; 2) spotty pattern cells (red arrows) 
and “very bright” cells (yellow arrows) appeared at DAP concentrations above the 
MIC; 3) DAP-TMR bound to the septum at sub-MIC DAP concentrations and around 
the MIC, but to the complete membrane at supra-MIC DAP concentrations. Next, we 
quantitatively analyzed the amount of cell-bound DAP in correlation to cell size and 
spotty pattern formation and DAP location on the cell membrane. 
 
65 
 
Figure 18: Representative images for localization of 5(6)-TAMRA-X, SE-labeled daptomycin 
(DAP-TMR) in Staphylococcus aureus. One hundred microliters of cells were incubated with a 
mixture of 0.1 µM DAP-TMR and increasing concentrations of non-labeled DAP in presence of 1 
mM Ca
2+
. Each sample was then imaged at different time points (0.5, 5, 10, 15, 20, and 25 min). 
Panel A: raw images with the same contrast setting; panel B: Image contrast and brightness were 
adjusted to visualize each cell. Red arrows: cells with spotty patterns; yellow arrows: “very bright” 
cells. Scale bar: 1 µm. 
4.1.3.1 Correlation between DAP-TMR intensity and cell size  
First, we analyzed the mean fluorescence intensity and size of each cell at each time 
point using the ImageJ program 
[217]
. Cell sizes were calculated from the measured 
cell diameter assuming round cell shapes. As shown in Fig. 19, for cells treated with 
sub-MIC DAP concentration (0.5 µM), the mean intensity and size per cell remained 
constant. However, for cells treated with DAP concentrations around the MIC (1 µM), 
the mean intensity and cell size were constant for the first 10 min of incubation. At 
longer incubation times, the intensity increased whereas the cell size decreased. Cells 
treated with DAP concentration higher than the MIC (6 µM and 10 µM) exhibited 
more drastic increase in the mean fluorescence intensity and decrease in cells size in 
an incubation time-dependent manner.  
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Figure 19: Quantitative analysis of fluorescence intensity and cell size. Mean fluorescence 
intensity and cell size at each time point were evaluated. The box represents 25th and 75th 
percentiles, the median is denoted by middle horizontal line, and the mean is indicated by small 
squares. Whiskers show 5-95 percentile and asterisks represent minimum and maximum values. 
Approximately 80 cells were analyzed at each time point. 
The correlation between mean fluorescence intensity and cell size was further 
analyzed; the mean intensity per cell was plotted against cell size, for each 
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concentration (Fig. 20). The data for the various time points were color-coded. For 0.5 
µM DAP, most data points distributed compactly in the area of low intensity and a 
cell size of 1-1.5 µm
2
. For 1 µM DAP, the points were more scattered at incubation 
time of 15, 20, and 25 min, implying that more points were located at higher intensity 
but smaller cell size (0.3-1.0 µm
2
). For 6 µM and 10 µM DAP, a negative correlation 
between fluorescence intensity and cell size was observed after 0.5 min. 
It has been reported that DAP does not induce cell lysis in S. aureus, and transmission 
electron microscopy (TEM) showed that cell membranes remained intact but the cells 
formed aberrant division septa 
[130]
. Studies of B. subtilis cells treated with sub-MIC 
DAP concentrations showed bent and elongated shapes 
[131]
. Our results indicate that 
strong DAP binding to the cell membrane results in reduction of the cell size in S. 
aureus. Interestingly, Chen and coworkers 
[218]
 proposed a lipid extracting mechanism, 
they found that DAP removed lipid molecules from giant unilamellar vesicles (GUVs) 
by forming lipid-peptide aggregates, resulting in a reduction of GUV size. The lipid 
extracting effect is dependent on the DAP concentration (around or supra-MIC) and 
in the presence of Ca
2+
 and PG, the same conditions required for DAP antibacterial 
acitivity. This indicates that a correlation may exist between the lipid extracting effect 
and the antibacterial activity of DAP. This mechanism by which DAP may remove 
lipids from the cell membrane that we observed can probably explain the reduction of 
cell size. 
 
68 
 
 
Figure 20: Correlation between 5(6)-TAMRA-X, SE-labeled daptomycin (DAP-TMR) intensity 
and cell size for different DAP concentrations. The mean fluorescence intensity of cells was 
plotted against cell size. Incubation time has been color-coded as indicated. 
4.1.3.2 Analysis of formation of spotty pattern cells and “very bright” cells 
As shown in Fig. 18, spotty pattern cells and cells that accumulated DAP-TMR 
densely, which we termed as “very bright” cells, appeared at supra-MIC DAP 
concentrations. Therefore, we calculated the percentages these two types of cells at 
each time point for each concentration (Fig. 21). The “very bright” cells were defined 
as cells with a mean fluorescence intensity value > 1 × 10
5. Neither the “very bright” 
nor the spotty patterns cells were observed when cells were treated with sub-MIC 
DAP concentration (0.5 µM); only a few “very bright” and spotty pattern cells were 
observed at longer incubation times (after 15 min) for cells treated with 1 µM DAP; 
and the percentages of both cell types increased steadily from 0.5 min to 25 min of the 
incubation time at supra-MIC DAP concentrations (6 µM and 10 µM). This indicated 
a positive correlation between DAP accumulation and spotty pattern formation.  
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Spotty patterns were also reported in the studies of B. subtilis by Poliano et al. 
[131]
 
and Müller et al. 
[140]
. Poliano demonstrated that DAP generates randomly positioned 
membrane patches at both lethal and sublethal doses and that such patches 
specifically recruit the cell division protein DivIVA, which can bind to negatively 
curved membranes; thus, DAP induces negative membrane curvature. However, 
Müller showed that such DAP-induced membrane patches do not cause membrane 
curvature and that DAP clusters fluid lipid (lipids with short, branched or unsaturated 
fatty acyl chains) domains by forming large DAP-fluid lipid complexes, thus affecting 
the overall membrane fluidity. A DAP-BDP FL labeled spiral pattern along the cell 
wall was reported in B. subtilis; this pattern is due to a preferential interaction with 
the membrane in PG-enriched regions. Studies of lipid vesicles showed that DAP 
molecules form oligomers on liposomes and that the oligomerization is dependent on 
Ca
2+
 and the presence of PG in the target membrane 
[143,219,220]
. 
Our results demonstrate that DAP induces spotty patterns in S. aureus only at 
concentrations around (1 µM) and above MIC (6 µM and 10 µM); this result is 
consistent with the report that DAP induces lipid-peptide aggregates on the surface of 
GUVs at concentrations of 1 µM and 5 µM but does not induce aggregates at 
concentration of 0.3 µM 
[218]
. This suggests that the spotty pattern and the bactericidal 
activity of DAP are correlated.  
Whether DAP targets on cell division proteins and how DAP acts on artificial 
membranes were further investigated in the following measurements.  
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Figure 21: Quantitative analysis of the “very bright” cells and spotty pattern cells. A: the counts of 
cells versus mean fluorescence intensity per cell at each time point. “Very bright” cells were 
defined as showing a mean fluorescence intensity value above 1×10
5
; B: percentage of “very 
bright” cells and spotty pattern cells at each time point. Incubation time has been color-coded as 
indicated. More than 300 cells were analyzed at each time point. 
4.1.3.3 Quantitative analysis of septum binding  
DAP is known to act at the cell membrane. However, as shown in Fig. 18, the 
distribution of DAP-TMR on the cell membrane is non-uniform for cells treated with 
different concentrations of native DAP or even for the same concentration at different 
incubation times. As mentioned earlier, DAP-TMR bound to the septum at sub-MIC 
concentrations and concentrations equal to the MIC, but to the complete membrane at 
supra-MIC concentrations. Hence, we quantitatively analyzed the distribution of 
DAP-TMR on the cell membrane as a function of time.  
The idea of our DAP-TMR distribution analysis is shown in Fig. 22. We analyzed the 
linear profile of cells with closed septum and the fluorescence intensity distribution 
along the red box (Fig. 22). The fluorescence profiles that showed one peak at septum 
with a ratio of septum/membrane ≈ 4, were characterized as septum binding (Fig 22. 
1), whereas the profiles that showed 3 peaks with a ratio of septum/membrane ≈ 2 
were characterized as membrane binding (Fig 22. 3).  
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Figure 22: Analysis of linear fluorescence profiles. Fluorescence images of cells stained with 5(6)-
TAMRA-X, SE-labeled daptomycin (DAP-TMR) and profiles of fluorescence intensity along the 
red box in the corresponding images. Analysis of linear fluorescence profiles for cells with closed 
septum. One peak (1) indicates septum binding, and yielded as a septum/membrane ratio ≈ 4; 
three peaks (4) indicate membrane binding, and yielded as a septum/membrane ratio of around 2.  
To demonstrate the discrimination between septum binding and membrane binding, 
we introduced the septum fusion protein FtsW-GFP and the membrane dye Nile red 
as controls (Fig. 21A). FtsW is an essential cell division protein that translocates lipid 
II to the extracellular side of the cell membrane and is localized to the septum; 
Genetic fusion of GFP (green fluorescent protein) to cell division proteins, such as 
FtsZ and FtsW have been widely used to visualize the division ring in situ 
[221]
. 
As shown in Fig. 23A, FtsW-GFP specifically accumulated at the division septum, 
and the ratio of fluorescence at the septum versus the lateral membrane is around 4. 
Nile red is a membrane dye that is homogeneously distributed over the entire cell 
membrane. The intensity of the fluorescent signal at the septum was about 1.5-fold 
higher than at the lateral membrane.  
As shown in Fig. 23B, septum binding was observed at sub-MIC DAP concentration 
(0.5 µM) for all incubation times tested, with median values above 2. However, for 
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cells treated with DAP concentration around the MIC (1 µM), septum binding was 
dominant for the first 10 min incubation with fluorescence ratios > 4; after 10 min of 
incubation, DAP was found to bind to the complete membrane with a fluorescence 
ratio approaching 2. Furthermore, for cells treated with supra-MIC DAP 
concentrations (6 µM and 10 µM), the overall membrane binding of DAP occurred 
for all incubation times with ratios around or below 2. Notably, at the concentration of 
6 µM, for the first 5 min incubation, the ratios are higher than those at other 
incubation time points.  
DAP has been reported to be rapidly bactericidal against both exponentially growing 
and stationary-phase S. aureus, suggesting that its bactericidal activity does not 
require cell division 
[222]
. However, our results strongly suggest that DAP initially 
binds to the division septum, which indicates a specific interaction with septum-
localized membrane components, and that the binding then extends to the complete 
membrane. In S. aureus, the septum is the only place where cell wall synthesis occurs 
[223]
; therefore, our findings indicate that DAP may interfere with the cell division and 
affect cell wall and lipid synthesis.   
These findings are in general agreement with those from early B. subtilis studies 
[131,150] 
, which reported that fluorescently labeled DAP preferentially binds to division 
septa and PG-enriched regions in a helical pattern along the long axis of the cell. 
Binding of DAP causes membrane distortions that alter the cell morphology and 
recruits cell division proteins. Defects in cell membrane and cell wall synthesis 
damage cell integrity, causing cell death. Additionally, B. subtilis cells treated with 
sub-MIC DAP concentration appeared bent and elongated, suggesting the inhibition 
of cell division 
[131]
. Aberrant division septa and multilobate morphology were also 
observed in S. aureus cells treated with supra-MIC DAP concentration 
[224]
. More 
recently, B. subtilis studies showed that DAP preferred to insert into the fluid 
membrane domains and clustered the fluid lipids, thus interfering with cell wall and 
lipid synthesis 
[140]
. 
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Figure 23: Quantitative analysis of septum binding. Septum binding was characterized by ratio of 
fluorescence intensities measured at the septum and the lateral membrane. A. Fluorescence 
microscopy images (a and b) showing controls with septum binding (FtsW-GFP) of median values 
≈ 4 and homogeneous binding (Nile red) of median values ≤ 2, respectively. B. Fluorescence 
ratios for cells treated with different DAP concentrations for different time points. For each time 
point, quantification was performed in at least 30 cells that displayed a closed septum. Horizontal 
lines correspond to median fluorescence ratio. Scale bar: 1 µm. 
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4.1.4 Super-resolution imaging of DAP-BDP FL molecules on S. aureus cells 
Although the specific target molecule of DAP is uncertain, it is well established that 
DAP target the cell membrane. uPAINT is a super-resolution imaging method that is 
ideally suited for studies of membrane-bound molecules. Therefore, uPAINT can be 
used to study the DAP binding behavior to the membrane of S. aureus at the single-
molecule level with high spatial precision. We thus implemented uPAINT on HILO 
microscopy to investigate the localization of single DAP-BDP FL molecules on the 
membrane of S. aureus cells. A mixture of 6 µM native DAP and 1 nM DAP-BDP FL 
and 1 mM Ca
2+
 was added onto exponential phase S. aureus cells  immediately before 
image acquisition.
   
Movies with 9,000 frames were recorded at a frame rate of 60 Hz within two time 
intervals 0 < t <3 min and 3 min < t < 6 min after DAP addition. Representative 
images obtained in the first time interval (upper panel) and the second time interval 
after DAP addition (lower panel) are shown in Fig. 24. Fluorescence images at 
different time points indicate different DAP-BDP FL molecules that localized on the 
membrane of S. aureus. The positions of single DAP-BDP FL molecules in each 
frame were determined by curve fitting and plotted together to construct super-
resolution images using the software thunderSTORM (Fig. 24B, D).  
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Figure 24: Fluorescence images and super-resolution images of BODIPY FL-labeled daptomycin 
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(DAP-BDP FL) molecules on the membrane of Staphylococcus aureus cells. Upper panel: 
representative images for the first 3 min after DAP addition; lower panel: representative images 
for the second 3 min after DAP addition. A and C: the corresponding summed up diffraction 
limited images; B and D: super-resolution images. Four cells were chosen for comparison. The 
number of molecules on septum (red box) and periphery of each cell were counted with the 
ImageJ program. 
We observed that DAP-BDP FL molecules constantly bound to the surface of cell 
membrane. Super-resolution images (Fig. 24B and D) showed that DAP-BDP FL 
molecules bound to both the septum and the periphery. We selected four cells that 
displayed a closed septum, analyzed the super-resolution images, and counted the 
number of molecules that bound to the septum and the periphery using ImageJ. Then, 
we compared the ratios of the numbers of molecules that localized on the septum to 
those localized on the periphery in the first 3 min (Table 7) and the second 3 min 
(Table 8) after DAP addition. In the first 3 min, more DAP-BDP FL molecules 
localized on the septum, and the ratios were either around 2 (cell 1 and cell 2) or 
above 2 (cell 3 and cell 4). However, in the second 3 min after DAP addition, more 
localizations were found on the periphery, and the ratios were below 1 for all the cells; 
for the cell 4, no septal localization was found. 
Table 7: Number of DAP-BDP FL molecules on the septum and periphery of each 
cell in the first 3 min after DAP addition. 
Cell Septum Periphery Ratio 
1 596 331 1.8 
2 368 207 1.8 
3 330 93 3.6 
4 382 50 7.6 
Table 8: Number of DAP-BDP FL molecules on the septum and periphery of each 
cell in the second 3 min after DAP addition. 
Cell Septum Periphery Ratio 
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1 225 270 0.8 
2 163 232 0.7 
3 86 116 0.7 
4 0 38 0 
These results further support our previous conclusion that DAP initially binds to the 
septum and then extends to the overall membrane at the single-molecule level.  
Furthermore, this also verifies that uPAINT is an ideal super-resolution imaging 
method to study the mechanism of other membrane-targeting antibiotics if the 
antibiotics can be labeled with a suitable fluorescent marker.  
On the basis of all the results presented above, we conclude that three phases of DAP 
binding to S. aureus exist (Fig. 25): (I) initial binding to the division septum, (II) 
extended binding to the envelope, and (III) finally, strong accumulation of DAP 
accompanied by formation of multiple spotty pattern cells and cell size reduction. The 
preferential binding of DAP to the division septum indicates that DAP might interact 
with septum-localized membrane components, thus interfering with cell wall and lipid 
synthesis.  
DAP exerts rapid bactericidal activity against both exponentially growing and 
stationary-phase S. aureus cells; this activity is superior to other antibiotics such as 
vancomycin, nafcillin, and linezolid 
[225]
. This effective bactericidal action may be 
attributed to the combination of effects on the division septum and membrane.  
 
Figure 25: Schematic representation of three different phases of daptomycin binding to cells of 
Staphylococcus aureus. Purple color demonstrates the distribution of DAP on the surface. This 
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model was suggested by Dr. Fabian  Grein. 
4.2 Colocalization of DAP with septum localized membrane components in S. 
aureus  
Although our studies clarified the phases of DAP binding, the existence of specific 
target molecules for DAP has not yet been confirmed. The quantitative analysis in 
section 1.4.3.3 proved the initial septum binding of DAP, indicating that DAP may 
specifically interact with septum-localized membrane components and interfere with 
cell wall and lipid synthesis. Therefore, we next examined the colocalization of 
fluorescently labeled DAP with two septum-localized membrane components: cell 
division protein FtsW and the cell wall precursor lipid II. 
4.2.1 Colocalization of DAP with FtsW  
FtsW is an integral membrane protein required for cell division in most bacteria. It 
belongs to the SEDS protein family, a large family of polytopic membrane proteins 
present in all bacteria with a PGN cell wall 
[ 226 , 227 ]
. SEDS proteins have been 
proposed to act as flippases, which function in the translocation of lipid II-linked 
PGN precursors from the inner to the outer leaflet of the cytoplasmic membrane. 
FtsW has been shown to localize to the division septum, and it is essential to recruit 
other division protein such as FtsI and interact with other proteins such as FtsZ and 
FtsI at the division site. As our previous results demonstrate that DAP preferentially 
binds to septum, the division protein could be a potential target of DAP. Therefore, 
we first investigated the colocalization of DAP with FtsW in S. aureus.  
To observe the localization of FtsW, we expressed FtsW-GFP fusion protein in S. 
aureus. For DAP localization, we incubated cells with a mixture of 1 µM DAP and 
0.1 µM DAP-TMR for 0.5 min in the presence of 1 mM Ca
2+
. This concentration of 
DAP is similar to the MIC mentioned earlier. Excess DAP-TMR and non-labeled 
DAP were removed by washing the cells in HEPES buffer immediately. Then, the 
colocalization of DAP-TMR with FtsW-GFP was investigated by combining HILO 
microscopy with dual-color imaging using a dual-emission image splitter.  
Two color images indicating the locations of FtsW-GFP and DAP-TMR on the cell 
membrane are shown in Fig. 26. Both FtsW-GFP and DAP-TMR were found to 
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localize at the septum. 
 
Figure 26: Two-color fluorescence images of 5(6)-TAMRA-X, SE-labeled daptomycin (DAP-
TMR) and FtsW-GFP fusion protein at the middle focal plane. Staphylococcus aureus cells 
expressing FtsW-GFP fusion protein were incubated with a mixture of 0.1 µM DAP-TMR and 1 
µM native DAP for 10 min in presence of 1 mM Ca
2+
. Scale bar: 1 µm. 
To acquire three-dimensional fluorescence images of the z-ring, the known 
localization site of FtsW-GFP, z-stacks were acquired for each of the two 
fluorescence color channels. A step size of 50 nm was used for acquiring z-stacks, 
and 61 images were acquired for each stack. This covered a distance of 3 µm, which 
is larger than the bacteria. Sixty-one images acquired for each color channel were 
summed up to create z-stack projection images. As shown in Fig. 27A, both DAP-
TMR and FtsW-GFP proteins were observed to localize to the cell septa. The stacks 
were then filtered and reconstructed in three-dimensions by the 3D Hybrid Median 
Filter function of ImageJ (Fig. 27B), to observe the complete structure of the z-ring. 
From the rotation images shown in Fig. 27C, we found that DAP-TMR and FtsW-
GFP were distributed all over the z-rings. These results demonstrate that at an 
incubation time of 0.5 min (the first phase of DAP binding), DAP-TMR and FtsW-
GFP colocalize to the septal z-ring. 
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Figure 27: Colocalization of 5(6)-TAMRA-X, SE-labeled daptomycin (DAP-TMR) and FtsW-
GFP fusion proteins in the septum. (A) z-stack maximum projection images of the corresponding 
color channels (B) one of the reconstructed three-dimensional images of each color channel (C) 
the three-dimensional images rotated through 180° (from left to right). Scale bar: 1 µm. 
According to our previous results, at longer incubation time, DAP binding extends 
over the envelop (Phase II). Therefore, we further examined the colocalization of 
DAP-TMR and FtsW-GFP at two different incubation time points (0.5 min and 20 
min).  
After incubation for 0.5 min, DAP-TMR and FtsW-GFP fusion protein colocalized to 
the septum as expected (Fig. 28). However, at 20 min, the distribution of FtsW-GFP 
remained unaffected, whereas DAP-TMR was bound to the complete cell membrane 
and interestingly, spotty patterns appeared.  
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It has been reported that the cell division protein DivIVA-GFP colocalized with DAP-
induced membrane patches in B. subtilis 
[131]
. DivIVA is an essential cell division 
protein that targets negatively curved membranes and localizes to the midcell region. 
As DAP was shown to induce membrane curvature, it was concluded that DAP 
recruits this cell division protein, thus leading to local changes in PGN biosynthesis. 
However, this conclusion remains controversial because another study reported that 
the DivIVA-GFP patches were proved to be artifacts due to the formation of GFP 
dimers 
[140]
. In contrast, DAP delocalizes different cell membrane proteins that are 
involved in cell wall synthesis, such as MurG, PlsX, and DivIVA in B. subtilis. 
Therefore, it was concluded that DAP does not target one specific protein but rather 
targets the fluid lipid areas. The fluid lipid domain was assumed to contain lipid II as 
well, because the long bactoprenol moiety of lipid II prefers a fluid lipid environment. 
Because FtsW can specifically transport lipid II from the inner to the outer leaflet of 
the cytoplasmic membrane, we speculate that FtsW might not be the specific target of 
DAP. Rather, the colocalization of FtsW-GFP and DAP observed at the earlier 
incubation interval is due to the fact that both of them can interact with lipid II. 
 
Figure 28: Colocalization of 5(6)-TAMRA-X, SE-labeled daptomycin (DAP-TMR) and FtsW-
GFP at different incubation time points. At 0.5 min, both were localized to the septum. At 20 min, 
DAP binding extended to the overall membrane and spotty pattern appeared (white arrows) 
whereas FtsW remained localized only to the septum. Scale bars: 1 µm. 
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4.2.2 Interaction of DAP with lipid II 
As our previous experiments suggested that DAP does not target the cell division 
protein FtsW, we investigated the interaction between DAP and cell wall precursor 
lipid II. As discussed in chapter 1.2, lipid II is a key component in PGN synthesis. It 
transports monomeric PGN units across the cell membrane for the cell biosynthesis. 
Because the structure of lipid II is highly conserved and difficult to modify, it has 
been a particularly attractive target of many antibiotics, such as nisin 
[228]
, plectasin 
[229]
 and vancomycin 
[230]
. 
Vancomycin elicits its bactericidal response by specifically binding to the sequence 
D-Ala–D-Ala of lipid II [230]; it effectively sequesters lipid II and prevents its normal 
incorporation into the growing PGN network, ultimately leading to cell death 
[231]
. 
Therefore, if lipid II is the target molecule of DAP, their interaction should be 
inhibited in cells pre-treated with vancomycin. 
Here, we used Van-BDP FL to label lipid II. In S. aureus, D-Ala–D-Ala residues are 
distributed all over the cell wall, even in the mature PGN 
[232]
; therefore, Van-BDP FL 
could bind to the complete membrane instead of the septum. Hence, we incubated the 
cells with D-serine, to promote the incorporation of this amino acid as the C-terminal 
residue of muropeptides in the cell wall, replacing the usual D-Ala to block the 
binding of Van-BDP FL. Therefore, Van-BDP FL can only specifically bind to the 
newly produced D-Ala–D-Ala residues at the septum [223]. S. aureus RN4200 was 
grown to an OD600 of 0.25 in TSB containing 0.125 M D-serine. Cells were then pre-
incubated with 1 µM Van-BDP FL for 2 min, excess Van-BDP FL was removed, and 
the cells were incubated with a mixture of 0.1 µM DAP-TMR and 1 µM unlabeled 
DAP for 10 min in the presence of 1 mM Ca
2+
. Cells were washed again and 
immobilized on an agarose pad and observed by fluorescence microscopy. Cells 
without Van-BDP FL pre-incubation and treated only with a mixture of 0.1 µM DAP-
TMR and 1 µM unlabeled DAP were considered as the control. 
As expected, for cells pre-incubated with Van-BDP FL, Van-BDP FL mostly 
localized to the septum (Fig. 29A, left panel), whereas DAP-TMR binding to the 
same cells was very faint (Fig. 29A, middle panel). The differences between cells 
with and without Van-BDP FL pre-incubation could be clearly observed and have 
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been indicated using circles with dashed yellow lines in the figure. Normal septum 
binding of DAP-TMR was clearly displayed for cells without vancomycin pre-
incubation (Fig. 29A, right panel). With vancomycin pre-incubation, the fluorescent 
intensity of DAP-TMR was almost two-fold lower than that of the control (Fig. 29B). 
These results indicate that the binding of Van-BDP FL clearly inhibits the interaction 
between DAP and the septum. As vancomycin specifically binds to lipid II, DAP 
might also interact with lipid II. 
 
Figure 29: BODIPY FL fluorescent vancomycin (Van-BDP FL) inhibits the interaction between 
daptomycin and lipid II. A: Two-color images of cells treated with Van-BDP FL and 5(6)-
TAMRA-X, SE-labeled DAP (DAP-TMR; left and middle) and cells treated with DAP-TMR only 
(control, right); B: quantitative analysis of intensity of DAP-TMR per cell. For each condition, 
quantification was performed in at least 100 cells. Standard errors of the mean are given by error 
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bars. 
Thus, we concluded that DAP might directly interact with lipid II at the septum, 
thereby interfering with the process of the cell wall biosynthesis. However, the 
precise interaction between DAP and lipid II and the precise binding site remain 
unclear. Lipid II has a large hydrophilic head group linked via a pyrophosphate to a 
long bactoprenol chain. Several lantibiotics and antimicrobial peptides, such as nisin, 
plectasin, and mersacidin have been reported to specifically bind to the pyrophosphate 
structure of lipid II. However, the interaction between lipid II and DAP might be 
simply considered as unspecific and driven by electrostatic attraction. The DAP-Ca
2+
 
complex functions as a cationic peptide and can easily attach to the pyrophosphate 
linked head group of lipid II. As vancomycin has a net charge of around 1 at pH 7, the 
binding of vancomycin may neutralize the negative charge, thus blocking the binding 
of the DAP-Ca
2+
 complex. Alternatively, vancomycin may occupy the binding site of 
DAP on the lipid II. 
A positive correlation between vancomycin and DAP susceptibilities in S. aureus has 
been reported, suggesting the existence of a cross-resistance machinery between these 
two antibiotics 
[233]
. Furthermore, it was proposed that such correlation is due to cell 
wall thickening, and the thickened cell wall may act as a physical barrier to DAP and 
vancomycin penetration; however, this explanation remains controversial 
[234]
. The 
recent report showed that fluorescently labeled vancomycin localizes to DAP-induced 
membrane patches and bent regions in Bacillus subtilis cells treated with a sublethal 
dose of DAP 
[131]
. This implies that the DAP-induced patches contains lipid II and that 
DAP may interfere with cell wall synthesis. More recently, DAP was found to prevent 
PGN synthesis by delocalizing the peripheral membrane protein MurG, which is 
responsible for the synthesis of lipid II. Moreover, DAP targets fluid lipid domains, 
which may contain lipid II as well, because the long bactoprenol moiety of lipid II 
prefers a fluid lipid environment 
[140]
. Collectively, these reports suggest that DAP 
may bind to one of the substrate or protein involved in cell wall synthesis and are in 
good agreement with our finding that DAP may interact with lipid II.  
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4.3 Specific interaction of DAP with lipid components in supported planar lipid 
bilayer 
Supported lipid bilayers are popular cell membrane models and are ideal for studying 
peptide binding. To visualize the binding of DAP to bilayers, we examined the 
interaction of fluorescently labeled DAP (DAP-BDP FL) with pure DOPC bilayer, 
and DOPC bilayer containing DOPG and/or several bactoprenol lipids by TIRF 
microscopy. TIRF microscopy is an established excellent method to study planar 
supported membranes because of its thin excitation depth. 
4.3.1 Interaction of DAP with different membranes lipid components 
We observed the preferential binding of DAP to the septum of S. aureus and 
identified that the cell wall precursor lipid II as a probable target. Next, we studied the 
binding behavior of DAP with respect to further membrane lipid components, 
including PG, lipid II, and its bactoprenol precursors C55-P and C55-PP.  
We integrated DOPG or/and C55-P, C55-PP, and lipid II into the DOPC bilayers. The 
negatively charged phospholipid PG has been shown to interact with DAP directly 
[219]
, and reduction of PG content leads to DAP resistance in B. subtilis 
[194]
. Therefore, 
we first studied the interaction of DAP with DOPG-containing bilayers. Bactoprenol 
lipids C55-P, C55-PP, and lipid II are the key components in cell wall biosynthesis and 
are all negatively charged phospholipids. Furthermore both lipid II and C55-PP 
contain a pyrophosphate group, which is a binding site of many antibiotics. Therefore, 
we assumed that these bactoprenol lipids could be the potential targets of DAP. All 
lipid chemical structures are shown in Fig. 30. Notably, the negatively charged head 
group of these lipids could increase affinity for DAP-Ca
2+
 complexes. 
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Figure 30: Chemical structures of lipids used in this study. 
Bilayers were prepared on coverslips by fusion of VSUVs. The neutral lipid DOPC 
was used as matrix to which PG or/and bactoprenol lipids (C55-P, C55-PP, and lipid II) 
with an amount of 0.1 mol% or 0.2 mol% were added. It has been reported that DAP 
destabilizes and induces fusion of lipid bilayers at higher concentrations 
[135]
. Hence, 
we added a mixture of 1 µM native DAP (MIC observed in susceptible bacteria) and 
50 nM DAP-BDP FL onto the lipid membranes in HEPES buffer in the presence of 1 
mM Ca
2+
.  
To ensure that the membranes were intact and fluid, FRAP assays were performed for 
the DOPC bilayer. We integrated 0.1 mol% TopFluor PC into the DOPC bilayer to 
make it visible. Fluorescent lipids were photobleached by exposing a part of the 
bilayer to a high-intensity laser beam, followed by a recovery monitoring with a low-
intensity laser beam. The fluorescence images and representative fluorescence 
recovery curves from the bleached region of interest (ROI) indicate that the DOPC 
bilayer remains intact and fluid (Fig. 31). 
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Figure 31: Fluorescence recovery after photobleaching (FRAP) analysis to examine the integrity of the 
supported lipid bilayer. A: Fluorescent images of a region of TopFluor PC-containing bilayers before 
and after local bleaching as well as the subsequent recovery. B: Representative fluorescence recovery 
curve from the bleached region (red circle). The photobleaching and recovery of a specific area 
shows that the bilayer remains intact and fluid. Lipid mixture: DOPC and 0.1 mol% TopFluor PC. 
Scale bar: 2 µm. 
Twelve types of bilayers with different lipid components were prepared, a mixture of 
50 nM DAP-BDP FL and 1 µM DAP was added onto each bilayer, and the layers 
were imaged using a TIRF microscope within 2 min after DAP addition. Movies with 
100 frames were recorded at a frame rate of 60 Hz. The differences of the amount of 
bound DAP-BDP FL molecules for each bilayer were determined by comparing the 
fluorescence intensity of the images. The mean values of average fluorescence 
intensity of each image for each sample was calculated. Representative images of 
each bilayer and quantified data are shown in Fig. 32. 
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Figure 32: Binding of BODIPY FL-labeled daptomycin (DAP-BDP FL) to fluid supported 
bilayers containing different molecular components. A: Representative total internal reflection 
fluorescence microscopy images of the binding of DAP to each bilayer. Movies with 100 frames 
were recorded at a frame rate of 60 Hz within 2 min after addition of DAP; B: Data were plotted 
as mean values of the time-averaged intensity of each movie. The data shown were obtained from 
at least 20 movies for each bilayer. The measurement was repeated three times and was 
reproducible. Standard errors of the mean are given by error bars. Significance of the differences 
between the values of the respective bilayers and the values determined for the DOPC bilayer was 
tested using Origin’s independent, two-sample t-test. *** indicates p < 0.001 and ** indicates 
p < 0.01. Scale bar: 5 µm. 
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As illustrated in Fig. 31, depending on the bilayer composition, the numbers of 
binding DAP-BDP FL molecules (average fluorescence intensity) strongly varied. For 
pure, electrically neutral DOPC membrane, only a low amount of DAP was observed.  
This is in agreement with a previous study showing that less DAP bound to the 
electrically neutral pure PC membranes compared to PC/PG membranes 
[218, 235]
. The 
binding of DAP-Ca
2+
 complexes to PC bilayers can occur because calcium leads to an 
increased exposure of the N-terminal acyl chain of the DAP molecule, allowing 
binding to the uncharged PC membrane 
[235]
. 
As expected, the presence of PG in the membrane enhanced the binding of DAP, and 
higher amounts of PG (0.2 mol%) induced higher amount of accumulations, resulting 
in a higher fluorescence intensities (0.1 mol% PG: p-value < 0.01; 0.2 mol% PG: p-
value < 0.001), compared to that in the DOPC membrane. The binding to PG-
containing membrane is considered as non-specific binding driven by the attractive 
electrostatic forces between the negatively charged PG and the positively charged 
DAP-Ca
2+
 complex. It has been reported that PG also triggers a conformation change 
of DAP molecules, enabling in deeper membrane penetration and oligomer formation 
[235]
. When the PG contents increased to 1 mol%, DAP-BDP FL strongly and 
homogeneously accumulated on the entire membrane, resulting in a very high 
fluorescence intensity, which was difficult to quantify (data not shown); hence, only 
0.1 mol% and 0.2 mol% PG-containing membranes were studied. 
The fluorescence intensity for membranes with 0.1 mol% of three bactoprenol lipids 
(C55-P, C55-PP, and lipid II) was higher than that of pure PC membranes. This was not 
surprising, as all these three bactoprenol lipids are negatively charged and increase the 
affinity for DAP-Ca
2+
 complexes. The intensity of the 0.1 mol% lipid II-containing 
membrane was higher than that of the 0.1 mol% PG-containing membrane, implying 
that DAP binds to lipid-II-containing membrane more strongly than to PG-containing 
membranes. This confirms our speculation that lipid II might be a target of DAP. 
Interestingly, the intensities of membranes containing 0.1 mol% C55-PP and 0.1 mol% 
C55-P were also higher than that of 0.1 mol% PG-containing membrane, indicating 
that these bactoprenol lipids are more attractive to DAP than PG is. However, the 
nature of interactions between DAP and bactoprenol lipids by hydrogen bonding or 
attractive electrostatic forces remains unclear.  
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Surprisingly, membranes containing 0.1 mol% PG and 0.1 mol% of each bactoprenol 
lipids (C55-P, C55-PP, and lipid II) triggered significantly stronger binding of DAP, 
indicating that the presence of PG considerably enhanced the binding of DAP to the 
bactoprenol lipids. The images showed dense accumulations of DAP on the 
membranes, resulting in evidently higher fluorescence intensity. The corresponding 
quantification revealed that these three types membrane showed significantly higher 
fluorescence intensities, compared to those of the other membranes tested (Fig. 32B). 
Such results were not observed when we increased the contents of each lipid from 0.1 
mol% to 0.2 mol%, suggesting that the dramatic increase in intensity was not simply 
due to a higher amount of negative charges.  
Collectively, these results demonstrate that DAP preferably binds to membranes 
containing both PG and bactoprenol lipids, compared to those containing only PG or 
only bactoprenol lipids. We concluded that DAP binding to the septum is not alone 
driven by opposite charges attracting each other, but rather by a more complex 
combinatorial effect of PG and bactoprenol lipids. 
4.3.2 Inhibition of DAP binding to bactoprenol precursors 
To further verify the specificity of DAP binding to membranes containing the 
bactoprenol precursors C55-P, C55-PP, and lipid II along with PG, these membranes 
were incubated with fruilimicin, bacitracin, and oritavancin, the antibiotics acting 
against these bactoprenol lipids, respectively (as discussed in 1.3.2.1) before DAP 
addition. If the binding of DAP-Ca
2+
 complex to the bactoprenol lipids is specific, 
such interactions should be inhibited by these competitive antibiotics. 
Fruilimicin is a cyclic lipopeptide that interrupts the cell wall precursor cycle by 
specifically forming of a complex with C55-P 
[160]
. Bacitracin inhibits PGN synthesis 
by sequestering C55-PP, thereby inducing the loss of cell integrity, leading to cell 
death 
[236]
. Oritavancin is an amphiphilic derivative of vancomycin, and it specifically 
binds to the D-Ala–D-Ala terminus of lipid II to inhibit PGN biosynthesis [237].  
Therefore, we pre-incubated the membranes containing 0.1 mol% PG and 0.1 mol% 
bactoprenol lipids (C55-P, C55-PP, and lipid II) with fruilimicin, bacitracin, and 
oritavancin, respectively (antibiotic to bactoprenol lipids ratio, 100:1) for 5 min. The 
excess unbound antibiotics was washed away, and the membranes were incubated 
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with a mixture of 50 nM DAP-BDP FL and 1 µM native DAP in the presence of 1 
mM Ca
2+
. The membranes were observed and imaged by TIRF microscopy within 2 
min after DAP addition.  
DAP-BDP FL molecules showed markedly decreased affinities for the membranes 
treated with the corresponding antibiotics, compared to the membranes without the 
antibiotic treatment, resulting in significant lower fluorescence intensity (Fig. 33A). 
The quantitative evaluation clearly showed a drastic decrease in the average 
fluorescence intensity in antibiotic-treated membranes, compared to that in the 
membranes without antibiotic pre-treatment (Fig. 33B). These results demonstrate 
that the binding of DAP to each bactoprenol lipid-containing membrane was inhibited 
by the corresponding specific antibiotics, thus proving the specificity in the 
interaction between DAP and the respective target molecules. 
Based on these observations, we conclude that the combination of PG and each of 
these three bactoprenol lipids (C55-P, C55-PP, and lipid II) in the membrane is crucial 
for DAP binding. However, the driving force for these interactions remains unclear. 
We suggest that the presence of negatively charged PG provides a more suitable 
environment for the interaction between DAP-Ca
2+
 complexes and bactoprenol lipids. 
Alternatively, PG may serve as scaffold and induce a confirmation change in DAP, 
thereby enabling the easy attachment of DAP to these bactoprenol lipids. 
In S. aureus, the septum is the only place where cell wall synthesis occurs, and all the 
three bactoprenol precursors are located at the septum and play key roles in teichoic 
acid biosynthesis. DAP preferably binds to C55-P, C55-PP, and lipid II in the presence 
of PG, probably locks these cell wall precursors by complex formation, thereby 
inhibiting PGN biosynthesis. This may explain the preferable binding of DAP to the 
septum in S. aureus cells during the first phase of DAP binding. 
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Figure 33: Inhibition of daptomycin (DAP) binding to the membranes containing the three 
bactoprenol lipids and phosphatidylglycerol (PG). A: TIRF images of DAP binding to each 
membrane. B: Data were plotted as mean values of the time-averaged intensity of each movies. 
The data shown were obtained from at least 20 movies for each membrane type. Standard errors of 
the mean are given by error bars. Significance was tested (independent, two-sample t-test) for the 
same membrane with and without antibiotic treatment; *** indicates p < 0.001. 
On the basis of the collective findings from this work, we propose a model for the 
action of DAP in S. aureus (Fig. 34). The binding of DAP to the membrane of S. 
aureus can be classified as specific septum binding (Fig. 34A) and non-specific 
peripheral membrane binding (Fig. 34B). Both the types of binding are crucial to its 
bactericidal activity against S. aureus. 
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Figure 34: Proposed model for daptomycin (DAP) action. A: Specific septum binding. DAP (blue) 
preferably binds to bactoprenol precursors [undecaprenyl phosphate (C55-P), undecaprenyl 
pyrophosphate (C55-PP), and lipid II] in the presence of phosphatidylglycerol (PG) at septum. B: 
Non-specific peripheral membrane binding. DAP causes membrane distortion, aggregate 
formation, and cell size reduction. 
Initially, the DAP-Ca
2+ 
complex specifically binds to the bactoprenol precursors (C55-
P, C55-PP, and lipid II) in the presence of PG at the septum. As DAP has been 
reported to flip between the two membrane leaflets 
[156]
, we suggest that DAP binds to 
these bactoprenol precursors on both leaflets of the membrane, forming DAP-
bactoprenol lipid-PG complexes to block the PGN synthesis cycles. Such complexes 
might inhibit certain enzymatic steps that use these bactoprenol precursors as the 
substrate. This hypothesis is consistent with a recent report that DAP delocalizes 
MurG, a membrane-associated transferase that catalyzes the synthesis of lipid II in B. 
subtilis 
[140]
. Notably, another important lipid precursor, lipid I, was not included in 
our studies; however, as lipid I is structurally similar to lipid II, we speculate the DAP 
might bind to lipid I as well. DAP-Ca
2+
 can directly bind to PG, driven by the 
attractive electrostatic forces; however, from our results, this binding is not dominant 
at the septum. It has been shown that fluorescently labeled DAP binds preferentially 
to the septa and forespore membrane in B. subtilis, because these areas are rich in PG 
95 
 
[150, 238 ]
. In contrast to the B. subtilis cell membrane, which contains many 
phospholipids in the membrane, such as LPG, polyglycerol phospholipid, CL, PE, and 
PG 
[239]
, the S. aureus cell membrane contains PG as the major phospholipid and it is 
distributed throughout the membrane. Therefore, if the interaction of DAP and PG is 
dominant in S. aureus, DAP should have bound to all the regions of the membrane, 
rather than binding preferentially to the septa. Without PG, the DAP-Ca
2+ 
complexes 
can also directly bind to each of the bactoprenol lipids. However, the binding 
efficiency in membranes containing only the bactoprenol lipids is remarkably lower 
than that in membranes containing both bactoprenol lipids and PG, indicating that PG 
plays a key role in the interaction of DAP with bactoprenol lipids.  
After the binding sites at the septa are saturated, DAP binding extends to the 
peripheral membrane, thereby causing membrane distortion, aggregate formation, and 
cell size reduction. The interactions between DAP and PG both in vivo and on the 
artificial membrane have been well investigated in many studies. Generally, the 
interaction is considered as non-specific binding driven by attractive electrostatic 
forces. DAP reaches the membrane in the presence of Ca
2+
 and inserts its short lipid 
tail into the membrane. PG triggers a conformation change and enables the deeper 
insertion of DAP and promotes oligomer formation, thus inducing membrane 
distortion and aggregate (spotty pattern) formation 
[235]
. We also observed cell size 
reduction caused by DAP; this finding is consistent with a previous report that DAP 
removed lipid molecules from GUVs by forming lipid-peptide aggregates, resulting in 
a reduction of GUV size 
[218]
. Because spotty pattern formation and cell size reduction 
were dependent on DAP concentration and incubation time, we speculate that these 
effects are associated with the bactericidal activity of DAP. 
Thus, we suggest both septum binding and peripheral membrane binding of DAP can 
eventually induce cell death. Septum binding contributes to inhibition of cell wall 
synthesis, whereas peripheral membrane binding contributes to membrane distortion 
and lipid removal from the membrane. 
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5. Summary  
DAP is a clinically important lipopeptide antibiotic, its bactericidal activity has been 
reported to be Ca
2+
 and PG dependent 
[240,75,137]
. Reduced PG content or increased 
conversion of PG to lysyl-PG promotes bacterial resistance to DAP 
[154,152]
. Despite a 
large number of studies, the exact mechanism of action of DAP is still incompletely 
understood.  
In this study, the mechanism of action of DAP was investigated. We studied the DAP 
binding behavior in S. aureus cells and attempted to identify its target molecule using 
several fluorescence imaging techniques. 
First, we studied the distribution of fluorescently labeled DAP on S. aureus cell 
membranes. We analyzed the distribution of DAP on S. aureus cell membranes as 
well as its correlation with cell size and spotty pattern formation in a time- and 
concentration-dependent manner. HILO microscopy was used to reduce background 
fluorescence. S. aureus cells were incubated with mixtures of DAP-TMR (100 nM) 
and native DAP at sub-MIC (0.5 µM), around MIC (1 µM), or supra-MIC (6 and 10 
µM) for varying time intervals. Septum binding was quantified in terms of the 
fluorescence ratio of DAP binding at the septum to lateral membrane. Septum binding 
was characterized by mean values of FR ≈ 4, whereas homogeneous membrane 
binding yielded mean values of FR ≈ 2. We observed septum binding for the DAP 
concentrations lower than the MIC for all incubations times tested (max. 25 min) and 
for the concentration around the MIC after 10 min of incubation. At longer incubation 
times and higher concentrations, homogeneous membrane binding of DAP occurred. 
DAP accumulation was negatively correlated with cell size but positively correlated 
with aggregate formation. The results from the use of a super-resolution imaging 
method, uPAINT, to study the binding of DAP-TMR to S. aureus at the single-
molecule level, further support the conclusion that DAP binds preferentially to the 
septum. On the basis of these observations, we postulate a three-phase process of 
DAP binding to S. aureus cells: (I) initial binding to the division septum, (II) 
extended binding to the envelope, and (III) strong accumulation of DAP accompanied 
by formation of multiple foci cells and cell size reduction.  
We further investigated the reason for such preferential binding of DAP to the septa 
97 
 
and attempted to identify a target molecule. For this, we studied the colocalization of 
DAP-TMR with two septum components, the cell division protein FtsW-GFP and the 
bactoprenol precursor lipid II by dual-color imaging microscopy. FtsW-GFP 
colocalized with DAP during the first phase of DAP binding at the septum; however, 
in the second phase, the distribution of the FtsW proteins remained unaffected, 
whereas DAP bound to the complete cell membrane. Treatment of S. aureus cells 
containing Van-BDP FL-labeled lipid II with a mixture of DAP-TMR and native 
DAP, revealed that the binding of DAP to the septum was inhibited by the 
vancomycin. This suggests that DAP interacts with lipid II. 
Finally, we used fluid supported lipid bilayers to study the binding behavior of DAP 
with respect to the lipid composition of the membrane. DAP binds to membranes in a 
Ca
2+
-dependent fashion 
[141]
, and it is known that anionic PG lipids are essential for 
effective DAP binding 
[149,150]
. Bilayers were prepared on coverslips by vesicle fusion. 
We used neutral PC phospholipids as matrix to which PG or/and bactoprenol lipids 
(C55-P, C55-PP and lipid II) were added with an amount of 0.1 mol% or 0.2 mol%. As 
expected, the presence of PG enhanced the DAP binding. Interestingly, the intensity 
in bactoprenol lipid-containing membranes was higher than that in 0.1 mol% PG-
containing membrane, indicating that DAP preferentially binds to these bactoprenol 
lipids rather than to PG. Notably, the addition of PG in each of bactoprenol-
containing membrane further strengthened the binding of DAP. To further verify the 
specificity of DAP binding to each of bactoprenol precursors, membranes containing 
C55-P, C55-PP, and lipid II along with PG, were pre-treated with fruilimicin 
[160]
, 
bacitracin 
[236]
, and oritavancin 
[237]
, respectively to block the DAP binding. The 
results confirmed the specificity in the interaction between DAP and bactoprenol 
lipids and PG. In fact, bactoprenol lipids affect the binding of DAP, and the 
combination of PG and bactoprenol lipids play a key role in the bactericidal 
mechanism of DAP.  
Further, as DAP was reported to form aggregates in solution, we studied aggregate 
formation in a mixture of varying concentrations of native DAP and fluorescently 
labeled DAP (DAP-BDP FL and DAP-TMR) in presence of Ca
2+ 
by using 
fluorescence correlation spectroscopy (FCS). We did not observed any aggregates 
(data not shown); this result is contradictory to those from other studies. This 
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discrepancy may be attributed to DAP conformational changes induced by the 
covalently attached fluorescent labels.  
In conclusion, we propose a new model for the binding of DAP to the septum of S. 
aureus, thereby providing important insights into the mechanism of action of DAP. 
However, the molecular mechanism of DAP binding to bactoprenol lipids in the 
presence of PG needs to be further investigated in the future studies.  
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